,Title,Interventions,Phases
0,study sd 101 combination localized low dose radiation patients untreated low grade b cell lymphoma,drug  sd 101 radiation  radiation therapi,phase 1 phase 2
1,bruton tyrosine kinase  btk  inhibition b cell lymphoma,drug  ibrutinib immunochemotherapi,phase 1
2,study evaluating cpi 1205 patients b cell lymphoma,drug  cpi 1205,phase 1
3,treatment mature b cell lymphoma leukaemia,drug  half cyclophosphamide drug  without copadm3 drug  mini cyve  without 3 maintenance courses drug  lmb b drug  lmb c,phase 3
4,incb050465 combination rituximab  bendamustine rituximab  ibrutinib participants previously treated b cell lymphoma  citadel 112 ,drug  incb050465 drug  rituximab drug  bendamustine drug  ibrutinib,phase 1
5,evaluation 4th generation safety designed car cells targeting high risk refractory b cell lymphoma,genetic  anti cd19 car cel,phase 1 phase 2
6,prognosis patients aggressive b cell lymphoma  treated rituximab anthracycline regimen,nan,nan
7,refractory diffuse large b cell lymphoma,nan,nan
8,bendamustine plus rituximab  br  relapsed progressive marginal zone b cell lymphoma  mzbcl ,drug  bendamustine plus rituximab,phase 2
9,novel autologou car therapy relapsed refractory b cell lymphoma,combination product  car ,phase 2
10,cd19 targeting car cells b cell lymphoma,biological  cd19 targeting car cells infus,phase 1 phase 2
11,cd19 cart cells patients relapse refractory cd19  b cell lymphoma ,drug  fludarabine drug  cyclophosphamide biological  cd19 cart,phase 1 phase 2
12,study investigate bgb 3111 chinese patients b cell lymphoma,drug  bgb 3111,phase 1
13,safety efficacy cart 19 cells relapse refractory patients cd19  b cell lymphoma,drug  cyclophosphamide drug  fludarabine biological  cart 19,phase 1
14,study compare bioequivalence safety jhl1101 rituximab cd20 positive b cell lymphoma pati,biological  jhl1101 biological  rituximab,phase 1
15,autologous cd19 car cells relapsed refractory b cell lymphoma,biological  autologous anti cd19 car cel,phase 1
16,study evaluate safety  tolerability  pk pd hlx01 patients cd20 positive b cell lymphoma,drug  hlx01,phase 1
17,phase ib study oral selinexor adult patients relapsed refractory b cell lymphoma receiving r dhaox r gdp,drug  selinexor drug  rituximab drug  dexamethasone drug  oxaliplatin drug  cisplatin drug  cytarabine drug  gemcitabin,phase 1
18,epstein barr virus status diffuse large b cell lymphoma,eber,nan
19,phase ii study comparing lr gem r gem p second line treatment diffuse large b cell lymphoma  legend ,drug  gemcitabine drug  methylprednisolone drug  rituximab drug  cisplatin drug  lenalidomid,phase 2
20,oxaliplatin prednisolone  ox p  patients relapsed refractory marginal zone b cell lymphoma mzl ,drug  oxaliplatin  prednisolon,phase 2
21,clinico pathologic study primary mediastinal b cell lymphoma,nan,nan
22,metformin combination standard induction therapy large b cell lymphoma  dlbcl ,drug  metformin drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  pegfilgrastim,phase 2
23,investigational drug study suberoylanilide hydroxamic acid relapsed diffuse large b cell lymphoma  0683 013 ,drug  mk0683  vorinostat  suberoylanilide hydroxamic acid  saha    duration treatment 6 month,phase 2
24,study assess pharmacokinetics safety recombinant human murine chimeric anti cd20 monoclonal antibody injection  ibi301  compared rituximab injection cd20 positive b cell lymphoma pati,drug  ibi301 drug  rituximab,phase 1
25,study anti cd22 car nk cells relapsed refractory b cell lymphoma,biological  anti cd22 car nk cel,early phase 1
26,study anti cd19 car nk cells relapsed refractory b cell lymphoma,biological  anti cd19 car nk cel,early phase 1
27,feasibility study adding bortezomib r ice chemotherapy treat relapsed  refractory diffuse large b cell lymphoma,drug  bortezomib  rituximab  ifosphamide  etoposide  carboplatin,phase 1
28,high dose sequential chemoimmunotherapy b cell lymphomas central nervous system involv,drug  high dose sequential chemotherapy autologous transpl,phase 2
29,trial r gemox versus r minichop regimen first line treatment elderly diffuse large b cell lymphoma,drug  rituximab drug  gemcitabine drug  oxaliplatin drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 3
30,high dose  absorbed dose adjusted 90y ibritumomab peripheral blood stem cells  pbsc  support b cell lymphoma,drug  90y ibritumomab,phase 1 phase 2
31,high dose chemotherapy rituximab adults aggressive large b cell lymphoma,drug  rituximab,phase 2
32,prognostic value clinical biological factors patients refractory relapsed diffuse large b cell lymphoma,nan,nan
33,study improving efficacy treatment diffused large b cell lymphoma pati,nan,nan
34,chidamide combined vddt regimen relapse refractory diffuse large b cell lymphoma,drug  chidamide drug  vinorelbine drug  liposomal doxorubicin mitoxantrone drug  dexamethasone drug  thalidomid,phase 2
35,study tisagenlecleucel combination pembrolizumab r r diffuse large b cell lymphoma pati,biological  tisagenlecleucel drug  pembrolizumab,phase 1
36,risk adapted therapy diffuse large b cell lymphoma,drug  rituximab  etoposide  cyclophosphamide  doxorubicin  vincristine prednisone  filgrastim,phase 2
37,cart 19 cells r r b cell lymphoma,cart 19 cel,phase 2 phase 3
38,cns prophylaxis diffuse large b cell lymphoma,drug  methotrex,phase 3
39,study 90y dota hll2 consolidation therapy r chop patients diffuse large b cell lymphoma,drug  90y dota hll2,phase 2
40,biocell natural killer mixture diffuse large b cell lymphoma  dlbcl  pati,biological  nkm inject,phase 3
41,study bendamustine ofatumumab elderly patients newly diagnosed diffuse large b cell lymphoma poor candidates r chop chemotherapi,drug  bendamustine drug  ofatumumab,phase 2
42,early response assessment diffuse large b cell lymphoma  dlcl  patients 18 fluoro 2 deoxyglycose positron emission tomography  fdg pet ,nan,nan
43,safety efficacy aeb071 everolimus patients cd79 mutant abc subtype diffuse large b cell lymphoma,drug  aeb071 drug  everolimu,phase 1
44,study aeb071  protein kinase c inhibitor  patients cd79 mutant diffuse large b cell lymphoma,drug  aeb071,phase 1
45,prospective cohort study central nervous system evaluation diffuse large b cell lymphoma,procedure  csf analysi,applicable
46,extended treatment access study mt 3724 subjects relapsed non hodgkin b cell lymphoma,drug  mt 3724,nan
47,high dose rituximab initial treatment indolent b cell lymphoma,drug  rituximab,phase 2
48,phase 2b open label study selinexor  kpt 330  patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  selinexor,phase 2
49,treatment elderly patients diffuse large b cell lymphoma,drug   r  chop regimen drug   r  cvp regimen,phase 4
50,association velcade r chop treatment b cell lymphoma,drug  rituximab  chop plus velcad,phase 2
51,mature b cell lymphoma leukemia study iii,drug  copad drug  cop  copd m3  cym drug  cop  copadm8  cyv,phase 2 phase 3
52,safety efficacy ipd1 cd19 ecar cells relapsed refractory b cell lymphoma,biological  ipd1 cd19 ecar cells drug  fludarabine cyclophosphamid,phase 1
53,lower dose decitabine based therapy patients refractory chemotherapy resistant solid tumors b cell lymphoma,drug  decitabine biological  cytokine induced killer cel,phase 1 phase 2
54,trial idelalisib patients relapsed diffuse large b cell lymphoma,drug  idelalisib,phase 2
55,study comparing efficacy safety g chop versus r chop untreated diffuse large b cell lymphoma pati,biological  g chop biological  r chop,phase 3
56,clinical trial decitabine relapse refractory diffuse large b cell lymphoma,drug  decitabin,phase 4
57,clinical study et190l1 artemis™ relapsed  refractory b cell lymphoma,biological  et190l1 artemis™ cel,phase 1
58,dose reduced consolidation radiation therapy patients diffuse large b cell lymphoma,radiation  radiation therapi,applicable
59,phase ii randomized study r dhap     bortezomib induction therapy relapsed refractory diffuse large b cell lymphoma  dlbcl  patients eligible transplantation  br dhap versus r dhap ,drug  r dhap drug  br dhap,phase 2 phase 3
60,study learn 200mg test drug  fostamatinib  helps people large b cell lymphoma type blood canc,drug  fostamatinib,phase 2
61,utility study diffuse large b cell lymphoma  dlbcl ,nan,nan
62,decitabine plus r chop diffuse large b cell lymphoma,drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  decitabin,phase 1 phase 2
63,real time molecular characterization diffuse large b cell lymphoma  dlbcl ,procedure  biological samples collect,nan
64,safety tolerability study incb053914 combination incb050465 diffuse large b cell lymphoma,drug  incb053914 drug  incb050465,phase 1
65,valproate first line therapy combination rituximab chop diffuse large b cell lymphoma,drug  valproate drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 1 phase 2
66,r eshap followed autologous transplantation refractory relapsed diffused large b cell lymphoma,drug  r eshap,phase 2
67,yttrium 90 ibritumomab tiuxetan  zevalin  beam relapsed low grade b cell lymphoma,drug  zevalin plus beam,phase 2
68,trial evaluate efficacy safety mor208 bendamustine  ben  versus rituximab  rtx  ben adult patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  rituximab  rtx  drug  mor208 drug  bendamustine  ben ,phase 2 phase 3
69,ibrutinib standard immuno chemotherapy younger  high risk patients diffuse large b cell lymphoma,drug  ibrutinib oral capsule  imbruvica  drug  r choep chemotherapi,phase 2
70,study venetoclax plus da epoch r treatment aggressive b cell lymphoma,drug  venetoclax drug  rituximab drug  etoposide drug  vincristine sulfate drug  cyclophosphamide drug  prednisone drug  doxorubicin hydrochlorid,phase 1
71,tak 659 participants relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  tak 659,phase 2
72,venetoclax plus r ice chemotherapy relapsed refractory diffuse large b cell lymphoma,drug  venetoclax drug  ric,phase 1
73,rituximab  cyclophosphamide  vincristine prednisone  r chop  plus metformin diffuse large b cell lymphoma,drug  metformin,phase 2
74,vtx 2337 combination radiotherapy patients low grade b cell lymphoma,drug  vtx 2337 plus radiotherapi,phase 1 phase 2
75,rhcacd20ma  hs006  combined chop  hi chop  patients previously untreated diffuse large b cell lymphoma,drug  hs006 chop drug  rituximab chop,phase 2
76,phase ii trial ifosfamide  etoposide  cytarabine  methotrexate  ivam  chemotherapy refractory relapsed diffuse large b cell lymphoma,drug  ifosfamide  etoposide  cytarabine  methotrexate  ivam  chemotherapi,phase 2
77,18f fdg pet scan mri diffusion evaluation early therapeutic response diffuse large b cell lymphoma,18f fdg pet scan mri diffus,applicable
78,study pegylated liposomal doxorubicin contrast epirubicin treatment diffuse large b cell lymphoma,drug  pl doxorubicin epirubicin,applicable
79,study compare efficacy safety jhl1101 versus rituximab patients previously untreated diffuse large b cell lymphoma  dlbcl ,biological  jhl1101 biological  mabthera,phase 3
80,study btk inhibitor bgb 3111 subjects relapsed refractory non gcb type diffuse large b cell lymphoma,drug  bgb 3111,phase 2
81,phase ii study oral panobinostat  lbh589  rituximab treat diffuse large b cell lymphoma  dlbcl ,drug  lbh589 drug  rituximab,phase 2
82,phase study continuous infusion immunotoxin igg rfb4 smpt dga refractory cd22 positive b cell lymphoma,drug  igg rfb4 smpt dga,phase 1
83,study mk 2206 patients relapsed refractory diffuse large b cell lymphoma,drug  mk2206,phase 2
84,pilot study dmri tool early evaluation tumor response diffuse large b cell lymphoma,procedure  diffusion mri,nan
85,safety efficacy study cnop chemotherapy diffuse large b cell lymphoma,drug  cyclophosphamide drug  vincristine drug  prednison,phase 1
86,phase ii study 131i rituximab relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  131i rituximab,phase 2
87,treatment diffuse large b cell lymphoma,drug  yangzhengxiaoji capsule combined chop regimen drug  chop regimen,phase 4
88,evaluation azd2014 alone combination rituximab relapsed refractory diffuse large b cell lymphoma,drug  azd 2014 drug  rituximab,phase 2
89,trial mosunetuzumab  btct4465a  consolidation therapy participants diffuse large b cell lymphoma following first line immunochemotherapy therapy participants previously untreated diffuse large b cell lymphoma unable tolerate full dose chemotherapi,drug  mosunetuzumab drug  tocilizumab,phase 1 phase 2
90,panobinostat rituximab relapsed refractory diffuse large b cell lymphoma,drug  panobinostat rituximab,phase 2
91,abbreviated 3 cycles rituximab plus chop cyclophosphamide  adriamycin  vincristine  prednisolone  immunochemotherapy patients completely excised localizedgastrointestinal cd cluster differentiation antigen 20    diffuse large b cell lymphoma,drug  abb r chop,phase 2
92,lenalidomide relapsed refractory primary cutaneous large b cell lymphoma leg type   multicentre prospective phase ii single arm trial french study group cutaneous lymphoma,drug  lenalidomid,phase 2
93,phase ib study btki cc 292 combined lenalidomide adults patients relapsed refractory b cell lymphoma,drug  cc 292   lenalidomid,phase 1
94,intensified 1st cycle rituximab plus 8th cycles r chop chemotherapy patients advanced bulky cd20  diffuse large b cell lymphoma  dlbcl ,drug  rituximab,phase 2
95,fdg pet stratified r dicep r beam asct diffuse large b cell lymphoma,procedure  autologous blood stem transplantation drug  r chop  rituximab  cyclphosphamide  etoposide  cisplatin  mesna  g csf,applicable
96,study comparing efficacy safety polatuzumab vedotin rituximab cyclophosphamide  doxorubicin  prednisone  r chp  versus rituximab cyclophosphamide  doxorubicin  vincristine  prednisone  r chop  participants diffuse large b cell lymphoma,drug  polatuzumab vedotin drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  vincristine placebo drug  prednisone drug  polatuzumab vedotin placebo,phase 3
97,efficacy consolidative involved site radiotherapy patients limited stage diffuse large b cell lymphoma,radiation  consolidation involved site radiotherapy  isrt  radiation  consolidation involved field radiotherapy  ifrt  drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 3
98,palliative benefit involved site radiotherapy patients advanced stage diffuse large b cell lymphoma,radiation  consolidation involved site radiotherapy  isrt  radiation  consolidation involved field radiotherapy  ifrt  drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 3
99,study lenalidomide evaluate safety effectiveness patients diffuse large b cell lymphoma  dlbcl ,drug  lenalidomide drug  gemcitabine drug  oxaliplatin drug  rituximab drug  etoposid,phase 2 phase 3
100,study ofatumomab combination ice chemotherapy patients diffuse large b cell lymphoma  dlbcl ,drug  ice  ofatumumab  ifosfamide  carboplatin  etoposide ,phase 2
101,ibrutinib patients refractory relapsed non gcb diffuse large b cell lymphoma non candidates autologous stem cell transpl,drug  ibrutinib drug  rituximab drug  gemcitabine drug  oxaliplatin drug  dexamethason,phase 2
102,ibrutinib lenalidomide dose adjusted epoch r subjects relapsed refractory diffuse large b cell lymphoma,drug  ibrutinib drug  part 1  dose level 1,phase 1 phase 2
103,avelumab combination regimens include immune agonist  epigenetic modulator  cd20 antagonist conventional chemotherapy patients relapsed refractory diffuse large b cell lymphoma  r r dlbcl ,biological  avelumab biological  utomilumab biological  rituximab azacitidine drug  bendamustine drug  gemcitabine drug  oxaliplatin,phase 3
104,gcs 100le combination etoposide dexamethasone relapsed refractory diffuse large b cell lymphoma,drug  gcs 100 drug  etoposide  dexamethason,phase 1 phase 2
105,study evaluate efficacy safety loncastuximab tesirine patients relapsed refractory diffuse large b cell lymphoma,drug  loncastuximab tesirin,phase 2
106,multicenter phase ii study evaluate clinical activity safety profile everolimus marginal zone b cell lymphomas  mzl ,drug  everolimu,phase 2
107,use pet early response evaluation patients diffuse large b cell lymphoma ,nan,nan
108,new combination chemoimmunotherapy systemic b cell lymphoma central nervous system involv,drug  methotrexate drug  rituximab drug  cytarabine drug  thiotepa drug  liposomial cytarabine drug  etoposide drug  ifosfamide drug  carmustine radiation  whole brain radiotherapi,phase 2
109,clinical trial determinate dose  security efficacy lenalidomide rituximab  lr  eshap patients diffuse large b cell lymphoma,drug  lr eshap  lenalidomide 5 mg  drug  lr eshap  lenalidomide 10 mg  drug  lr eshap  lenalidomide 15 mg  drug  lr eshap  lenalidomide 20 mg ,phase 1 phase 2
110,study bevacizumab  avastin  combination rituximab  mabthera  chop  cyclophosphamide  hydroxydaunorubicin  doxorubicin   oncovin  vincristine   prednisone  chemotherapy patients diffuse large b cell lymphoma,drug  bevacizumab drug  rituximab drug  chop drug  placebo,phase 3
111,azd2014 plus novel anti cancer agents relapsed refractory diffuse large b cell lymphoma,drug  azd2014 drug  ibrutinib,phase 1
112,treatment resistance related gene expression profile diffuse large b cell lymphoma,nan,nan
113,akt inhibitor mk2206 treating patients relapsed refractory diffuse large b cell lymphoma,drug  akt inhibitor mk2206 laboratory biomarker analysis pharmacological studi,phase 2
114,study evaluating kte c19 combination atezolizumab subjects refractory diffuse large b cell lymphoma  dlbcl ,biological  axicabtagene ciloleucel drug  atezolizumab  anti pd l1 ,phase 1 phase 2
115,randomized  open label  two arms  phase iii comparative study assessing role involved mediastinal radiotherapy rituximab containing chemotherapy regimens patients newly diagnosed primary mediastinal large b cell lymphoma,observation radiation  3d conformal radiotherapy  3d crt ,applicable
116,clinical study blinatumomab patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  blinatumomab,phase 2
117,reduced radiation patients diffuse large b cell lymphoma,radiation  radiation therapi,applicable
118,kpt 330 plus rice relapsed refractory aggressive b cell lymphoma,drug  kpt 330 drug  rituximab drug  etoposide drug  carboplatin drug  ifosfamide drug  dexamethason,phase 1
119,tgr 1202 ibrutinib treating patients relapsed refractory diffuse large b cell lymphoma,drug  ibrutinib laboratory biomarker analysis drug  pi3k delta inhibitor tgr 1202,phase 2
120,bendamustine plus subcutaneous rituximab patients diffuse large b cell lymphoma,drug  bendamustine  rituximab,phase 2
121,ofatumumab ivac salvage chemotherapy diffuse large b cell lymphoma pati,drug  ofatumumab drug  etoposide drug  ifosfamid drug  mesna drug  cytarabine drug  methotrexate drug  leukovorin drug  granulocyte colony stimulating factor,phase 2
122,efficacy study rituximab asct high risk diffuse large b cell lymphoma,drug  acvbp drug  ace drug  rituximab procedure  autologous stem cell transpl,phase 3
123,combination sar3419 rituximab relapsed refractory diffuse large b cell lymphoma,drug  sar3419 drug  rituximab,phase 2
124,phase ii trial r chop   azacytidine diffuse large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  vincristine drug  doxorubicin drug  prednisone drug  azacytidin,phase 1 phase 2
125,phase iii study rad001 adjuvant therapy poor risk patients diffuse large b cell lymphoma  dlbcl  rad001 versus matching placebo patients achieved complete response first line rituximab chemotherapi,drug  everolimus drug  everolimus placebo,phase 3
126,sar3419 single agent relapsed refractory diffuse large b cell lymphoma  dlbcl  pati,drug  sar3419,phase 2
127,treatment relapsed  refractory diffuse large b cell lymphoma,drug  apatinib,phase 4
128,study navitoclax addition bendamustine rituximab patients relapsed diffuse large b cell lymphoma  navigate ,drug  bendamustine drug  navitoclax drug  rituximab,phase 2
129,safety efficacy blinatumomab subjects newly diagnosed high risk diffuse large b cell lymphoma,drug  blinatumomab drug  investigator choice chemotherapi,phase 2
130,rituximab  ifosfamide  carboplatin  etoposide  rice  followed gallium nitrate  rituximab dexamethasone  gard  relapsed refractory diffuse large b cell lymphoma,drug  rice drug  gard treat,phase 2
131,131i rituximab relapsed refractory marginal zone b cell lymphoma,drug  131i rituximab,phase 2
132,acp 196  btk inhibitor  treatment de novo activated b cell  abc  subtype diffuse large b cell lymphoma,drug  acp 196,phase 1
133,phase ii study tumor targeting human l19 il2 monoclonal antibody cytokine fusion protein combination rituximab relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  l19 il2   ph drug  l19 il2 rd   ph ii drug  rituximab,phase 1 phase 2
134,pidilizumab treating patients stage iii iv diffuse large b cell lymphoma following first remiss,laboratory biomarker analysis biological  pidilizumab,phase 2
135,everolimus plus rituximab relapsed refractory diffuse large b cell lymphoma,drug  everolimus drug  rituximab,phase 2
136,epigenetic modulation relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  rad001 drug  lbh589 drug  doublet  rad001 lbh589 ,phase 2
137,study evaluate safety  pharmacokinetics  clinical activity combination ro6870810 venetoclax  without rituximab  participants relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  ro6870810 drug  venetoclax drug  rituximab,phase 1
138,phase ib ii study efficacy safety r cmc544 r gemox combination diffuse lage b cell lymphoma first second relap,drug  rituximab  cmc544  gemcitabine oxaliplatin,phase 1 phase 2
139,da edoch14 r poor prognosis diffuse large b cell lymphoma,drug  dexamethasone dose dense immunochemoterapi,phase 2
140,bendamustine combined rituximab patients relapsed refractory diffuse large b cell lymphoma,drug  bendamustine drug  rituximab,phase 2
141,dose dense chemotherapy rituximab young high risk diffuse large b cell lymphoma patients  cry 04 ,drug  r choep14x6 hd arac hd mtx,phase 2
142,study evaluate lenalidomide combined dexamethasone relapsed refractory diffuse large b cell lymphoma,drug  cc 5013  lenalidomide  drug  dexamethason,phase 2
143,study r acvbp regimen supported pegfilgrastim high risk diffuse large b cell lymphoma,drug  rituximab   acvbp regimen plus pegfilgrastim procedure  autologous stem cell transpl,phase 2
144,r chop b bevacizumab diffuse large b cell lymphoma,drug  bevacizumab  rituximab,phase 2
145,study obinutuzumab combination chop chemotherapy versus rituximab chop participants cd20 positive diffuse large b cell lymphoma  goya ,drug  rituximab drug  obinutuzumab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 3
146,lenalidomide  ixazomib  rituximab front line therapy high risk indolent b cell lymphoma,drug  ixazomib drug  lenalidomide drug  rituximab,phase 1 phase 2
147,ibrutinib combination lenalidomide rituximab participants relapsed refractory diffuse large b cell lymphoma,drug  ibrutinib drug  lenalidomide drug  rituximab,phase 1 phase 2
148,study evaluate safety efficacy dasatinib  sprycel  subjects relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  dasatinib,phase 2
149,safety efficacy medi 551 combination immunomodulating therapies subjects aggressive b cell lymphoma,drug  medi 551 12 mg kg drug  medi0680 2 5 mg kg drug  medi0680 10 mg kg,phase 1 phase 2
150,study evaluating efficacy axicabtagene ciloleucel compared standard care therapy subjects relapsed refractory diffuse large b cell lymphoma,drug  axicabtagene ciloleucel drug  platinum containing salvage chemotherapy  eg  r ice  followed high dose therapy  eg  beam  autologous stem cell transplant responders ,phase 3
151,response study yt90 zevalin patients diffuse large b cell lymphoma 6 cycles chop,drug  chemotherapy followed zevalin,phase 2
152,study combination velcade  rituximab  cyclophosphamide  doxorubicin  prednisone rituximab  cyclophosphamide  doxorubicin  vincristine  prednisone patients newly diagnosed non germinal center b cell subtype diffuse large b cell lymphoma,drug  velcade drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  prednisone drug  vincristin,phase 2
153,study ibrutinib combination rituximab chop epstein barr virus positive diffuse large b cell lymphoma,drug  ibrutinib drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisolon,phase 2
154,indication transplant patients high risk b cells lymphoma metabolic complete remission ,procedure  autograft,nan
155,bendamustine  obinutuzumab  dexamethasone older patients diffuse large b cell lymphoma,drug  bendamustine hydrochloride biological  obinutuzumab drug  dexamethasone quality life assessment laboratory biomarker analysi,phase 2
156,phase ii trial thalidomide refractory relapsed diffuse large b cell lymphoma hodgkin disea,drug  thalidomid,phase 2
157,rituximab combination chemotherapy treating patients diffuse large b cell non hodgkin lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  etoposide drug  filgrastim drug  pegfilgrastim,phase 3
158,improving outcome high risk aggressive b cell lymphoma patients nivolumab maintenance therapi,biological  nivolumab,phase 2
159,anti cd19 tcrζ chimeric antigen receptor cells treatment cd19  b cell lymphoma,biological  il 2 pre treated cd19 cells biological  il 7 il 15 pre treated cd19 cel,phase 4
160,indolent non follicular lymphomas prognostic project,treatment  watch wait policy includ,nan
161,safety  pharmacokinetic pharmacodynamic effect ka2237  pi3 kinase p110β δ inhibitor  b cell lymphoma,drug  ka2237,phase 1
162,study rituximab bendamustine without brentuximab vedotin cd30 positive diffuse large b cell lymphoma,drug  brentuximab vedotin drug  rituximab drug  bendamustin,phase 2
163,multicentre study determine cardiotoxicity r chop compared r comp patients diffuse large b cell lymphoma,drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  liposomal doxorubicin drug  vincristin drug  prednisolon,phase 2
164,study atezolizumab combination either obinutuzumab plus bendamustine obinutuzumab plus     cyclophosphamide  doxorubicin  vincristine  prednisone  chop  participants follicular lymphoma  fl  rituximab   chop participants diffuse large b cell lymphoma  dlbcl ,drug  atezolizumab drug  bendamustine drug  cyclophosphamide drug  doxorubicin drug  obinutuzumab drug  prednisone drug  vincristine drug  rituximab,phase 1 phase 2
165,study mini chop plus ofatumumab treat cd 20  diffuse large b cell lymphoma patients aged 80 year,drug  ofatumumab,phase 2
166,multicenter prospective registry study diffuse large b cell lymphoma,nan,nan
167,r ceop 90 r ceop 70 versus r chop 50 treatment diffuse large b cell lymphoma follicular lymphoma grade 3b,drug  r ceop 70 drug  r ceop 90 drug  r chop 50,phase 3
168,study evaluate safety efficacy adeno ifn gamma cutaneous b cell lymphoma,genetic  adenovirus interferon gamma,phase 2
169,study roflumilast combination standard chemotherapy high risk diffuse large b cell lymphoma,drug  roflumilast,phase 1
170,study safety efficacy cc 122 combined rchop newly diagnosed dlbcl poor risk factor,drug  avadomide  cc 122  drug  rituximab drug  cyclophosphamide 750mg m2 iv infusion drug  vincristine drug  prednison,phase 1 phase 2
171,study comparing gb241 rituximab patients b cell non hodgkin lymphoma,biological  gb241 biological  rituximab,phase 1
172,study assess effectiveness rchop without velcade previously untreated non germinal center b cell like diffuse large b cell lymphoma pati,drug  bortezomib drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 2
173,combination rituximab varlilumab immunotherapy patients b cell lymphoma,drug  varlilumab,phase 1 phase 2
174,study l nddp  aroplatin  patients advanced solid malignancies b cell lymphoma,drug  aroplatin,phase 1
175,mabthera  rituximab  combination chop  chop like  chemotherapy patients aggressive b cell lymphoma,drug  cyclophosphamide drug  hydroxydaunorubicin drug  oncovin drug  prednisone drug  rituximab,nan
176,rituximab standard chop vs rituximab bi weekly chop untreated stage iii iv low grade b cell lymphoma  jcog0203 ,drug  rituximab   standard chop drug  rituximab   bi weekly chop,phase 2 phase 3
177,thiotepa  busulfan fludarabin pt refractory early relapsed aggressive b cell non hodgkin lymphoma,drug  thiotepa drug  busulfan drug  fludarabin procedure  transplant  hct  radiation  cytoreduction drug  immunosuppression drug  cyclosporine drug  methotrexate drug  atg procedure  collection infusions donor pbsc,phase 2
178,safety  tolerability pk btk inhibitor dtrmwxhs 12 patients b cell lymphoma,drug  dtrmwxhs 12,phase 1
179,study obinutuzumab  polatuzumab vedotin  lenalidomide relapsed refractory follicular lymphoma  fl  rituximab combination polatuzumab vedotin lenalidomide relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  lenalidomide drug  obinutuzumab drug  polatuzumab vedotin drug  rituximab,phase 1
180,safety efficacy bexxar therapy treatment relapsed residual b cell lymphoma autologous transpl,drug  bexxar,phase 1
181,dose dense chemotherapy   rituximab    intensified high dose chemoimmunotherapy support peripheral autologous stem cell diffuse large b cell lymphoma,drug  rituximab drug  ciclofosfamide drug  doxorubicina drug  vincristina drug  prednisone drug  pegfilgrastim drug  mitoxantrone drug  ara c drug  lenograstim drug  bcnu drug  vp 16 procedure  asct,phase 3
182,evaluate efficacy armodafinil patients b cell lymphoma severe fatigu,drug  armodafinil drug  placebo,applicable
183,study bortezomib plus gdp treatment refractory relapsed non gcb dlbcl,drug  bortezomib drug  gemcitabine drug  dexamethasone drug  cisplatin,phase 2
184,study participant preference subcutaneous versus intravenous mabthera rituxan participants cd20  diffuse large b cell lymphoma cd20  follicular non hodgkin lymphoma grades 1  2 3a,drug  cyclophosphamide  hydroxydaunorubicin  oncovin  prednisone prednisolone  chop  drug  cyclophosphamide  vincristine  prednisone prednisolone  cvp  drug  bendamustine drug  rituximab,phase 3
185,proteasome inhibitor ps 341 relapsed refractory b cell lymphomas previously treated chemotherapi,drug  ps341  bortezomib ,phase 2
186,lenalidomide  mtx  ara c rituximab relapsed aggressive b cell lymphoma,drug  lenalidomid,phase 1 phase 2
187,phase 2  multicenter  randomized  open label study medi 551 adults relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  medi 551 2 mg kg drug  rituximab drug  ice drug  dhap procedure  autologous stem cell transplant  asct  drug  medi 551 4 mg kg,phase 2
188,rituximab plus chop chemotherapy diffuse large b cell lymphoma,drug  r chop,phase 2
189,observational study evaluating efficacy safety preemptive antiviral therapy tenofovir hbsag positive patients diffuse large b cell lymphoma receiving rituximab chop chemotherapy  speed study ,nan,nan
190,study safety tolerability pci 32765 patients recurrent b cell lymphoma,drug  pci 32765,phase 1
191,treatment protocol nhl bfm nopho study groups mature aggressive b cell lymphoma leukemia children adolesc,drug  rituximab window drug  additional doses rituximab drug  cyclophosphamide drug  cytarabine drug  dexamethasone drug  doxorubicin hydrochloride drug  vindesine sulfate drug  etoposide drug  ifosfamide drug  methotrexate drug  prednisolone drug  vincristin,phase 3
192,safety study btk inhibitor  dtrmwxhs 12  used singly combination  cll b cell lymphoma,drug  dtrmwxhs 12 drug  dtrm 505 drug  dtrm 555,phase 1
193,study pembrolizumab  mk 3475  participants relapsed refractory primary mediastinal large b cell lymphoma relapsed refractory richter syndrome  mk 3475 170 keynote 170 ,biological  pembrolizumab,phase 2
194,phase study ac0010 patients cll  sll  mcl  dlbcl nhl,drug  ac0010ma,phase 1
195,efficacy safety pz01 treatment patients r r cd19  b cell acute lymphoblastic leukemia b cell lymphoma,drug  pz01 car cel,phase 1
196,impact cd34  cell dose progression free survival following high dose therapy autologous stem cell transplantation relapsed refractory diffuse large b cell lymphoma  dlbcl ,procedure  leukapheresis drug  plerixafor drug  carmustine  etoposide  cytarabine  melphalan procedure  autologous stem cell transplant,phase 2
197,study obinutuzumab  ro5072759  ga101   combination chop chemotherapy patients previously untreated advanced diffuse large b cell lymphoma  gather ,drug  obinutuzumab drug  cyclophosphamide drug  doxorubicin drug  prednisone drug  vincristin,phase 2
198,early phase evaluation abc294640 patients refractory relapsed diffuse large b cell lymphoma kaposi sarcoma,drug  abc294640,phase 1 phase 2
199,study evaluating inotuzumab ozogamicin  cmc 544  plus rituximab diffuse large b cell non hodgkin lymphoma,drug  inotuzumab ozogamicin  cmc 544  drug  rituximab,phase 2
200,mini chop rituximab patients aged 80 year,drug  r mini chop,phase 2
201,pilot study ruxolitinib relapsed refractory hodgkin lymphoma primary mediastinal large b cell lymphoma,drug  ruxolitinib,phase 2
202,dose escalation study clofarabine patients relapsed refractory low grade intermediate grade b cell lymphoma,drug  clofarabin,phase 1
203,rituximab gemcitabine patients relapsed refractory diffuse large b cell lymphoma,drug  rituximab drug  gemcitabin,phase 2
204,safety efficacy study btk inhibitor subjects relapsed refractory diffuse large b cell lymphoma,drug  ibrutinib,phase 2
205,ibrutinib  bortezomib rituximab chop treatment elderly patients cd20  dlbcl  ipi ≥ 2,drug  ibrutinib bortezomib   r chop,phase 1 phase 2
206,r megachop eshap beam patients high risk aggressive b cell lymphoma,procedure  immunotherapy procedure  induction treatment part 1 procedure  induction treatment part 2 pbpc collection procedure  induction treatment part 3 procedure  consolidation treatment part 1  hd chemotherapy asct radiation  consolidation treatment part 2  radiotherapi,phase 2
207,ibrutinib combination chemotherapy treating patients relapsed refractory diffuse large b cell lymphoma,drug  carboplatin drug  etoposide drug  ibrutinib drug  ifosfamide laboratory biomarker analysis pharmacological study biological  rituximab,phase 1
208,phase 1 study evaluating safety efficacy c car011 treatment dlbcl subject,biological  c car 011,phase 1
209,study inotuzumab ozogamicin   temsirolimus patients relapsed refractory cd22  b cell nhlymphoma,drug  inotuzumab ozogamicin drug  temsirolimu,phase 1
210,study rtxm83 plus chop chemotherapy versus rituximab plus chop therapy patients non hodgkin lymphoma,biological  rtxm83,phase 3
211,ps 341 alone ps 341 plus epoch chemotherapy treat non hodgkin lymphoma,drug  ps 341 drug  etoposide drug  doxorubicin drug  vincristine drug  cyclophosphamide drug  prednisone drug  filgrastim,phase 2
212,rituximab hypercvad  r hcvad  alternating rituximab methotrexate cytarabine   r mc  newly diagnosed patients diffuse large b cell lymphoma myc rearrangement ,drug  r hcvad r mc,phase 2
213,study zevalin versus observation patients least 60 yrs old newly diagnosed diffuse large b cell lymphoma pet negative complete remission r chop r chop like therapi,drug  zevalin  ibritumomab tiuxetan ,phase 3
214,cd19 22 car cells  auto3  treatment diffuse large b cell lymphoma,biological  auto3,phase 1 phase 2
215,study gdc 0853 patients resistant b cell lymphoma chronic lymphocytic leukemia ,drug  gdc 0853,phase 1
216,clinical prognostic value sarcopenia patients older 70 years diffuse large b cell lymphoma,procedure  anthropometric measur,applicable
217,situ vaccine low grade lymphoma  combination intratumoral flt3l poly iclc low dose radiotherapi,drug  rhuflt3l cdx 301 drug  poly iclc,phase 1 phase 2
218,study obinutuzumab combined lenalidomide treatment relapsed refractory follicular aggressive b cell lymphoma,drug  lenalidomide ga101,phase 1 phase 2
219,phase ii study evaluate combination rituximab depocyte® c5r chemotherapy protocol patients ages 18 60 years primary cerebral non hodgkin lymphoma systemic diffuse large b cell lymphoma neuromeningeal invasion diagnosi,drug  rituximab drug  cytarabin,phase 2
220,romidepsin  gemcitabine  dexamethasone cisplatin treatment peripheral cell diffuse large b cell lymphoma,drug  gemcitabine drug  dexamethasone drug  cisplatin drug  romidepsin,phase 1
221,trial lenalidomide given maintenance therapy relapsed diffuse large b cell lymphoma,drug  lenalidomid,phase 2
222,r±ceop90 versus r±ceop75 newly diagnosed young patients medium high risk dlbcl,drug  high dose epirubicin combined cvp ± rituximab drug  standard dose epirubicin combined cvp ± rituximab,phase 3
223,yt90 zevalin combination chemotherapy  z chop treating patients stage ii  stage iii  stage iv diffuse large b cell lymphoma,drug  yttrium 90  labeled ibritumomab tiuxetan  zevalin ,phase 2
224,multicentre  randomized phase iii study rituximab maintenance treatment versus observation patients aggressive b cell lymphoma  nhl 13,drug  rituximab,phase 3
225,combination chemotherapy  shr 1210 decitabine relapsed refractory pmbcl,drug  decitabine drug  gvd chemotherapy drug  shr 1210,phase 1 phase 2
226,study evaluating safety tolerability inotuzumab ozogamicin  cmc 544  japanese patients b cell non hodgkin lymphoma  nhl ,drug  inotuzumab ozogamicin  cmc 544 ,phase 1
227,cd19 car cells patients relapsed refractory cd19 positive b cell lymphoma,biological  cd19 car cel,phase 1
228,oral panobinostat adult patients dlbcl relapsed refractory stem cell transfusion  asct  eligible asct,drug  panobinostat,phase 2
229,r chop alone vs  r chop plus radiotherapy localized cd20  dlbcl,drug  r chop radiation  radiotherapi,phase 3
230,study brentuximab vedotin combined rchop rchp front line treatment patients diffuse large b cell lymphoma  dlbcl ,drug  brentuximab vedotin drug  rituximab drug  vincristine drug  cyclophosphamide drug  prednisone drug  doxorubicin,phase 2
231,nanochip technology monitoring treatment response detecting relapse participants diffuse large b cell lymphoma,procedure  molecular nanotechnolog,applicable
232,safety efficacy bendamustine  gemcitabine  rituximab  nivolumab  begern  patients r r dlbcl,drug  bendamustine hydrochloride drug  gemcitabine 500 mg drug  gemcitabine 700 mg drug  gemcitabine 1000 mg drug  nivolumab drug  rituximab,phase 1 phase 2
233,treatment patients diffuse large b cell lymphoma suitable anthracycline containing chemotherapi,drug  cyclophosphamide drug  vincristine drug  prednisolone drug  rituximab drug  inotuzumab ozogamicin drug  gemcitabin,phase 2
234,blinatumomab consolidation post autologous stem cell transplantation patients diffuse large b cell lymphoma  dlbcl ,drug  blinatumomab procedure  autologous stem cell transplant drug  carmustine drug  etoposide drug  cytarabine drug  melphalan procedure  peripheral blood draw,phase 1
235,trial r gemox regimen previously untreated elderly patients dlbcl ,drug  r gemox,phase 2
236,storm  temsirolimus  rituximab dhap relapsed refractory diffuse large b cell lymphoma,drug  rituximab  temsirolimus  dhap  intraven,phase 2
237,nivolumab ipilimumab primed immunotransplant dlbcl,drug  ipilimumab drug  nivolumab,phase 1 phase 2
238,study brentuximab vedotin  rituximab  dose attenuated chp elderly patients diffuse large b cell lymphoma  dlbcl ,drug  brentuximab vedotin drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  prednison,phase 2
239,treatment advanced b cell lymphoma,drug  rituximab drug  cytarabin,phase 2
240,study ym155 refractory diffuse large b cell lymphoma  dlbcl  subject,drug  ym155,phase 2
241,intergroup trial children adolescents primary mediastinal large b cell lymphoma  da epoch rituximab evalu,drug  etoposide  doxorubicin  vincristine  cyclophosphamide  rituximab,phase 2
242,abbreviated r chop completely excised stage ii dlbcl,drug  rituximab plus chop immunochemotherapi,phase 2
243,dose escalation study patients relapsed refractory dlbcl myd88 l265p mut,drug  imo 8400,phase 1 phase 2
244,study abt 199 plus ibrutinib rituximab patients relapsed refractory diffuse large b cell lymphoma,drug  abt 199 drug  ibrutinib drug  rituximab,phase 1
245,study tazemetostat participants relapsed refractory b cell non hodgkin lymphoma ezh2 gene mut,drug  tazemetostat,phase 2
246,observational study mabthera rituxan  rituximab  combination chop chemotherapy first line patients diffuse large b cell lymphoma,nan,nan
247,phase 1 study tazemetostat patients relapsed refractory b cell non hodgkin lymphoma,drug  tazemetostat,phase 1
248,idelalisib rituximab  ifosfamide  carboplatin  etoposide  rice  children adolesc,drug  idelalisib drug  rituximab drug  ifosfamide drug  carboplatin drug  etoposid,phase 1
249,trial radiotherapy durvalumab dlbcl,drug  durvalumab radiation  radiotherapi,phase 1
250,clinical trial chinese patients b cell non hodgkin lymphoma gb226 ,biological  gb226,phase 2
251,phase ii study rituximab cyclophosphamide  doxorubicin  vincristine  prednisone  chop  patients gastric diffuse large b cell non hodgkin lymphoma,drug  rituximab   chop chemotherapi,phase 2
252,molecular monitoring circulating tumor dna nivolumab mainten,drug  nivolumab  iv  240 mg,early phase 1
253,study sgn 35  brentuximab vedotin  patients relapsed refractory pmlbcl,drug  brentuximab vedotin,phase 2
254,observational study mabthera rituxan  rituximab  plus chemotherapy first line treatment patients diffuse large b cell lymphoma follicular lymphoma,nan,nan
255,chidamide r chop regimen dlbcl pati,drug  chidamide   r chop regimen,phase 2
256,chidamide plus dice regimen patients relapse refractory b cell non hodgkin lymphoma  nhl ,drug  chidamide plus dice regimen,phase 2
257,erythropoietin management anemia caused chemotherapi,drug  darbepoetin alfa drug  r chop,phase 2
258,study assess enzastaurin   r chop subjects dlbcl genomic biomarker dgm1™,drug  enzastaurin hydrochloride r chop   placebo,phase 3
259,linfotargam  treatment chemotherapy plus rituximab highly active antiretroviral therapy patients diffuse large b cell lymphoma infection human immunodeficiency virus  hiv ,drug  r chop drug  highly active antiretroviral therapy drug  central nervous system  cns  prophylaxis drug  prophylaxis opportunistic infections support treat,phase 4
260,safety efficacy bkm120 relapsed refractory nhl,drug  buparlisib,phase 2
261,study evaluate safety efficacy mosunetuzumab  btct4465a  combination polatuzumab vedotin b cell non hodgkin lymphoma,drug  mosunetuzumab drug  polatuzumab vedotin drug  rituximab drug  bendamustine drug  obinutuzumab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  tocilizumab,phase 1
262,study hmpl 523 patients relapsed refractory mature b cell neoplasm,drug  hmpl 523,phase 1
263,r chop14 r chop21  consolidation pet oriented radiotherapy  rt  dlbcl pati,drug  treatment plan,phase 2
264,ipilimumab rituximab treating patients relapsed refractory b cell lymphoma,biological  ipilimumab laboratory biomarker analysis biological  rituximab,phase 1
265,cyber association relapsed refractory dlbcl,drug  rituximab drug  bendamustine drug  cytarabin,phase 2
266,study lenalidomide revlimid  plus rituximab  revlirit regimen  elderly patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  lenalidomide plus rituximab,phase 2
267,mabioncd20® compared mabthera® lymphoma pati,drug  rituximab drug  doxorubicin drug  vincristine drug  cyclophosphamide drug  prednison,phase 3
268,chidamide plus r chop elderly dlbcl,drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  chidamid,phase 2
269,phase ib ii study investigating safety  tolerability  pharmacokinetics  efficacy mosunetuzumab  btct4465a  combination chop chp polatuzumab vedotin participants b cell non hodgkin lymphoma,drug  mosunetuzumab drug  polatuzumab vedotin drug  rituxumab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  tocilizumab,phase 1 phase 2
270,ga newly diagnosed diffuse large b cell lymphoma,drug  ga101 drug  rituximab drug  doxorubicin drug  cyclophosphamide drug  prednisone drug  bleomycin drug  vindesin drug  vincristin,phase 3
271,reduced chemotherapy low risk dlbcl,drug  rituximab drug  cyclophosphamide drug  epirubicin drug  vincristine drug  prednison,phase 4
272,efficacy safety study mdv9300 patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,biological  mdv9300,phase 2
273,dose adjusted epoch r myc positive dlbcl,drug  da epoch r,phase 2
274,copanlisib nivolumab treating participants recurrent refractory diffuse large b cell lymphoma primary mediastinal large b cell lymphoma,drug  copanlisib laboratory biomarker analysis biological  nivolumab,phase 2
275,medi4736 alone combination tremelimumab azd9150 adult subjects relapsed refractory dlbcl  d4190c00023 ,drug  medi4736 drug  tremelimumab drug  azd9150,phase 1
276,velcade®  bortezomib  rituximab subjects relapsed refractory indolent b cell lymphoma,drug  velcade rituximab,phase 2
277,pharmacokinetic study comparing sct400 rituximab patients b cell non hodgkin lymphoma,drug  sct400 drug  rituximab,phase 2
278,study dpx survivac vaccine therapy patients recurrent survivin expressing dlbcl,biological  dpx survivac drug  cyclophosphamid,phase 2
279,study evaluate efficacy safety subsequent treatment zevalin  ibritumomab tiuxetan  elderly  60 years  patients diffuse large b cell lymphoma 4 cycles chop21 rituximab  chop21 r  therapi,drug  chop21 r drug  zevalin,phase 2
280,study evaluate safety efficacy lenalidomide mor00208 patients r r dlbcl,drug  mor00208 drug  lenalidomid,phase 2
281,phase ii study combination chop 21  obinutuzumab ibrutinib untreated young high risk dlbcl patients ,drug  obinutuzumab drug  ibrutinib drug  chop,phase 2
282,bortezomib maintenance high risk dlbcl,drug  bortezomib,phase 2
283,study betalutin treatment relapsed refractory non hodgkin lymphoma  lymrit 37 05 ,drug  betalutin,phase 1
284,gp2013 japanese patients cd20 positive low tumor burden indolent b cell non hodgkin lymphoma,drug  gp2013,phase 1
285,interim pet ct guided cycle numbers r chop dlbcl,drug  r chop,phase 2
286,da epoch rituximab metformin  rm  double hit lymphoma,drug  metformin,phase 2
287,lenalidomide plus ice treatment refractory relapsed dlbcl,drug  lenalidomide drug  ifosfamide drug  carboplatin drug  etoposid,phase 2
288,rice ibrutinib relapsed dlbcl,drug  ibrutinib ric,phase 2
289,study efficacy safety ctl019 adult dlbcl pati,biological  ctl019,phase 2
290,study bi 1206 combination rituximab subjects indolent b cell non hodgkin lymphoma,biological  bi1206,phase 1 phase 2
291,safety  pharmacokinetics pharmacodynamics recombinant chimeric anti cd20 monoclonal antibody patients b cell non hodgkin lymphoma ,biological  chimeric anti cd20 monoclonal antibodi,phase 1
292,rituximab combination chemotherapy without lenalidomide treating patients newly diagnosed stage ii iv diffuse large b cell lymphoma,drug  cyclophosphamide drug  doxorubicin hydrochloride laboratory biomarker analysis drug  lenalidomide drug  prednisone biological  rituximab drug  vincristine sulf,phase 2
293,study evaluate bruton tyrosine kinase  btk  inhibitor pci 32765 patients recurrent mature b cell neoplasm,drug  pci 32765,phase 1
294,study pralatrexate treat patients relapsed refractory b cell non hodgkin lymphoma,drug  pralatrexate injection dietary supplement  vitamin b12 dietary supplement  folic acid,phase 2
295,study evaluating tru 015 b cell non hodgkin lymphoma,biological  tru 015,phase 1 phase 2
296,efficacy lenalidomide combination subcutaneous rituximab   minichop dlbcl patients 80 ,drug  lenalidomide drug  rituximab,phase 3
297,provide initial evidence safety  pharmacokinetics  pharmacodynamics  efficacy support pivotal ct p10 therapeutic equivalence tri,biological  rituximab,phase 1
298,btk inhibitor bgb 3111 chinese patients large b cell lymphoma  non gcb  indolent lymphoma  fl mzl ,drug  bgb 3111,phase 2
299,zevalin twice aggressive non hodgkin lymphoma,drug  90y ibritumomab tiuxetan,phase 2
300,gene therapy b cell non hodgkin lymphoma using cd19 car gene transduced lymphocyt,drug  cyclophosphamide bendamustine genetic  dose level  1 genetic  dose level 1 genetic  dose level 2 genetic  dose level 3,phase 1 phase 2
301,chemotherapy monoclonal antibody radioimmunotherapy high risk b cell non hodgkins lymphoma,drug  cyclophosphamide drug  etoposide drug  rituximab drug  cytarabine drug  doxorubicin drug  tositumomab,phase 2
302,car cell receptor immunotherapy patients b cell lymphoma,drug  fludarabine drug  cyclophosphamide biological  anti cd19 car pbl,phase 1 phase 2
303,phase study alisertib   r epoch treatment myc positive aggressive b cell lymphoma,drug  alisertib,phase 1
304,first line antibiotic therapy early stage hp    gastric pure dlbcl,drug  lansoprazole  amoxicillin  clarithromycin  metronidazol,phase 2
305,rituximab pembrolizumab treating patients relapsed refractory follicular lymphoma diffuse large b cell lymphoma,laboratory biomarker analysis biological  pembrolizumab biological  rituximab,phase 2
306,study ontak patients relapsed refractory  b cell non hodgkin lymphoma,drug  ontak  denileukin diftitox ,phase 2
307,study evaluating cmc 544 b cell non hodgkin lymphoma,drug  inotuzumab ozogamicin  cmc 544 ,phase 1
308,effect blinatumomab mrd dlbcl subjects post ahsct,drug  blinatumomab,phase 2
309,study evaluating inotuzumab ozogamicin  cmc 544  administered combination rituximab subjects non hodgkin lymphoma  nhl ,drug  inotuzumab ozogamicin drug  rituximab,phase 1 phase 2
310,atezolizumab  gemcitabine  oxaliplatin  rituximab treating patients relapsed refractory transformed diffuse large b cell lymphoma,drug  atezolizumab drug  gemcitabine laboratory biomarker analysis drug  oxaliplatin biological  rituximab,phase 1
311,study combining ibrutinib rituximab  cyclophosphamide  doxorubicin  vincristine  prednisone patients cd20 positive b cell non hodgkin lymphoma,drug  part 1  cohort 1 drug  part 1  cohort 2 drug  part 1  cohort 3 drug  part 2  cohort 1 drug  part 2  cohort 2,phase 1
312,external beam radiotherapy zevalin management indolent b cell non hodgkin lymphoma,external beam radiotherapy plus 90 ibritumomab tiuxetan,phase 1
313,pilot study standard dose rituximab  ifosfamide  carboplatin etoposide  rice  plus bortezomib  velcade  dose escalating fashion patients relapsed primary refractory aggressive b cell non hodgkin lymphoma candidates autologous stem cell transpl,drug  rituximab  ifosfamide  carboplatin  etoposide  bortezomib,early phase 1
314,rituximab  lenalidomide  nivolumab treating participants relapsed refractory non germinal center type diffuse large b cell lymphoma primary central nervous system lymphoma,biological  nivolumab biological  rituximab drug  lenalidomid,phase 1 phase 2
315,pk pd  safety tolerability multiple dose regimens mt 3724 gemcitabine oxaliplatin treatment patients relapsed refractory diffuse large b cell non hodgkin lymphoma  mt 3724 nhl 002 ,drug  mt 3724,phase 2
316,pk  pd  safety  tolerability multiple dose regimens mt 3724 treatment patients relapsed non hodgkin b cell lymphoma b cell chronic lymphocytic leukemia,drug  mt 3724,phase 1
317,study canfosfamide refractory relapsed mantle cell  diffuse large b cell lymphoma multiple myeloma,drug  canfosfamide hcl inject,phase 2
318,study evaluate safety  tolerability  pharmacokinetics  efficacy amg 562 subjects r r diffuse large b cell lymphoma  mantle cell lymphoma  follicular lymphoma,drug  amg 562,phase 1
319,study mocetinostat selected patients mutations acetyltransferase genes relapsed refractory diffuse large b cell lymphoma follicular lymphoma,drug  mocetinostat,phase 1 phase 2
320,rituximab addition chemotherapy autologous stem cell transplantation treatment diffuse large b cell lymphoma,drug  rituximab drug  epirubicin drug  cyclophosphamide drug  vincristine drug  prednisone drug  granulocyte colony stimulating factor drug  mitoxantrone drug  cytarabine ara c drug  dexamethasone drug  carmustine bcnu drug  etoposide drug  melphalan radiation  radiotherapy procedure  pbsc reinfus,phase 2
321,open label study investigating safety efficacy blinatumomab combination pembrolizumab  keynote 348 ,drug  blinatumomab drug  pembrolizumab,phase 1
322,optimal 60   dr  chop  improvement therapy elderly patients cd20  dlbcl using rituximab optimized liposomal vincristin,drug  conventional vincristine drug  liposomal vincristine drug  ricover scheme rituximab drug  optimised rituximab schedul,phase 3
323,phase 1 2  multicenter  open label study aeg35156 patients relapsed refractory chronic lymphocytic leukemia indolent b cell lymphoma,drug  aeg35156 antisense iv infus,phase 1 phase 2
324,study evaluate efficacy tolerability debio 1562 combination rituximab patients relapsed refractory dlbcl forms nhl,drug  debio 1562 drug  rituximab,phase 2
325,ga101 minichop regimen treatment elderly unfit patients diffuse large b cell non hodgkin lymphoma,drug  ga101,phase 2
326,study evaluate efficacy safety cudc 907 patients rr dlbcl  including patients myc alt,drug  cudc 907,phase 2
327,phase ii study dose adjusted epoch rituximab adults untreated burkitt lymphoma c myc  diffuse large b cell lymphoma,drug  epoch r drug  epoch rr,phase 2
328,rituximab plus bendamustine front line treatment frail elderly   70 years  patients dlbcl  phase ii multicenter study fil,drug  bendamustine rituximab,phase 2
329,pk pd  safety tolerability multiple dose regimens mt 3724 lenalidomide treatment patients relapsed refractory diffuse large b cell non hodgkin lymphoma  mt 3724 nhl 003 ,drug  mt 3724,phase 2
330,study lenalidomide combination rice lenalidomide maintenance post auto transplant dlbcl,drug  revlimid,phase 1 phase 2
331,study pinatuzumab vedotin  dcdt2980s  combined rituximab polatuzumab vedotin  dcds4501a  combined rituximab obinutuzumab participants relapsed refractory b cell non hodgkin lymphoma  nhl ,drug  obinutuzumab drug  pinatuzumab vedotin drug  polatuzumab vedotin drug  rituximab,phase 1 phase 2
332,long term follow study clinical study subjects treated actr087,actr087,nan
333,bendamustine   rituximab older patients previously untreated diffuse large b cell lymphoma,drug  bendamustine drug  rituximab,phase 2
334,ledipasvir sofosbuvir sofosbuvir velpatasvir pts indolent bcell lymphoma associated hcv infect,drug  ledipasvir sofosbuvir drug  sofosbuvir velpatasvir,phase 2
335,study evaluating safety tolerability combination therapy inotuzumab ozogamicin  cmc 544  rituximab,drug  inotuzumab ozogamicin  cmc 544  drug  rituximab  rituxan ,phase 1
336,feasibility study induction maintenance avelumab plus r chop patients diffuse dlbcl  avr chop studi,drug  avelumab,early phase 1
337,safety  tolerability  pharmacokinetics  immunoregulatory study urelumab  bms 663513  subjects advanced metastatic solid tumors relapsed refractory b cell non hodgkin lymphoma,drug  urelumab  bms 663513 ,phase 1
338,mln4924 compared mln4924 plus chemotherapy large b cell lymphoma,drug  mln4924 drug  etoposide drug  prednisone drug  vincristine drug  cyclophosphamide drug  doxorubicin drug  rituximab drug  filgrastim,phase 1 phase 2
339,pharmacokinetic pharmacodynamic study comparing hlx01 rituximab patients cd20 positive  b cell lymphoma,drug  hlx01 drug  rituximab,phase 1 phase 2
340,tolerance pharmacokinetics shr1459 patients recurrent replased refractory mature b cell neoplasmstumor,drug  shr1459,phase 1
341,phase ii study vismodegib patients refractory relapsed b cell lymphoma chronic lymphocytic leukemia,drug  vismodegib,phase 2
342,phase 1b 2 safety tolerability study medi6469 combination therapeutic immune agents monoclonal antibodi,biological  medi6469 monotherapy biological  medi6469 plus tremelimumab biological  medi6469 plus durvalumab biological  medi6469 plus rituximab,phase 1 phase 2
343,early treatment stratification based pet scan response chemotherapy patients diffuse large b cell lymphoma,drug  r megachop,phase 2
344,venetoclax  ibrutinib  prednisone  obinutuzumab  revlimid  vipor  relapsed refractory b cell lymphoma,drug  venetoclax drug  ibrutinib drug  prednisone drug  obinutuzumab drug  revlimid  lenalidomide ,phase 1
345,atezolizumab  rituximab  gemcitabine oxaliplatin patients relapsed refractory dlbcl suitable high dose therapi,drug  atezolizumab drug  rituximab drug  gemcitabine 1000 mg drug  oxaliplatin 100 mg,phase 2
346,ibrutinib treating patients relapsed refractory transformed indolent b cell non hodgkin lymphoma,drug  ibrutinib laboratory biomarker analysi,applicable
347,study bkm120   rituximab patients relapsed refractory indolent b cell lymphoma,drug  pi3k inhibitor bkm120 biological  rituximab pharmacodynamics correlative studi,phase 1
348,treatment study denintuzumab mafodotin  sgn cd19a  plus rice versus rice alone diffuse large b cell lymphoma,drug  denintuzumab mafodotin drug  rituximab drug  ifosfamide drug  carboplatin drug  etoposid,phase 2
349,optimized donor selection  nonmyeloablative bmt b cell lymphomas post transplantation cy rituximab,drug  fludarabine drug  cyclophosphamide radiation  total body irradiation drug  tacrolimus drug  mycophenolate mofetil drug  rituximab biological  allogeneic bone marrow transplant  bmt ,phase 2
350,phaseⅰb study evaluating safety efficacy c car011 treatment b  nhl subject,biological  cd19 directed car cel,phase 1
351,marginal zone lymphoma cohort korea,rituximab,nan
352,phase iii study syb l 0501 combination rituximab treat recurrent relapsed diffuse large b cell lymphoma,drug  rituximab,phase 3
353,comparative study efficacy safety lipegfilgrastim comparison pegfilgrastim elderly patients aggressive b cell non hodgkin lymphomas high risk r chop 21 induced neutropenia,drug  lipegfilgrastim drug  pegfilgrastim,phase 3
354,study rituximab  cyclophosphamide  doxorubicin liposomal  myocet®   vincristine  prednisone   r comp  treat non hodgkin lymphoma,drug  rituximab drug  cyclophosphamide drug  vincristine drug  prednisone drug  doxorubicin,phase 2
355,efficacy   safety treatment r nimp relapsed aggressive lymphoma,drug  rituximab drug  vinorelbine drug  ifosfamide drug  mitoxantrone drug  prednison,phase 2
356,treatment aggressive localized lymphoma,drug  rituximab drug  doxorubicin drug  vincristine drug  prednisone procedure  radiotherapi,phase 3
357,retrospective analysis rituximab containing immunochemotherapy burkitt burkitt like lymphoma adult,intervention  observational study ,nan
358,safety antitumor activity study loncastuximab tesirine   ibrutinib diffuse large b cell mantle cell lymphoma,drug  loncastuximab tesirine ibrutinib,phase 1
359,cd19 chimeric receptor expressing lymphocytes b cell non hodgkin lymphoma  cl,genetic  cd19car 28 zeta cells drug  ipilimumab,phase 1
360,rituximab plus chop sargramostim patients newly diagnosed diffuse large b cell lymphoma,drug  rituximab,phase 2
361,carfilzomib  rituximab  ifosfamide  carboplatin  etoposide treating patients relapsed refractory stage iv diffuse large b cell lymphoma,drug  carboplatin drug  carfilzomib drug  etoposide drug  ifosfamide laboratory biomarker analysis pharmacological study biological  rituximab,phase 1 phase 2
362,dna sequencing based monitoring minimal residual disease predict clinical relapse aggressive b cell non hodgkin lymphoma,collected pre treatment tumor biopsy peripheral blood tests device  pet ct,applicable
363,combination rituximab nk immunotherapy b lymphoma,drug  rituximab biological  nk immunotherapi,phase 1 phase 2
364,mln8237 patients relapsed refractory aggressive b cell lymphoma treated rituximab     vincristin,drug  alisertib  mln8237  drug  rituximab drug  vincristin,phase 1 phase 2
365,phase ii study fil elderly frail patients dlbcl,drug  rituximab dexamethasone lenalidomid,phase 2
366,pembrolizumab relapsed refractory gray zone lymphoma  gzl   primary central nervous system lymphoma  pcnsl   extranodal diffuse large b cell lymphoma,drug  pembrolizumab,phase 2
367,sequential therapy cd19 targeted cd20 targeted car cell therapy diffuse large b cell lymphoma dlbcl ,biological  anti cd19 car cells anti cd20 car cel,phase 1 phase 2
368,efficacy safety study syb l 0501 combination rituximab patients untreated  low grade b cell non hodgkin lymphoma mantle cell lymphoma,drug  syb l 0501 drug  rituximab,phase 2
369,procurement follicular b cell lymphoma cells purpose possible use future clinical tri,procedure  procurement follicular b cell lymphoma cel,nan
370,sequential infusion anti cd19 anti cd20 car cells relapsed refractory b cell lymphoma,biological  mixed cd19 cd20 car transf,phase 1 phase 2
371,tailoring treatment b cell non hodgkin lymphoma based pet scan results mid treat,drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  ondansetron drug  dexamethasone drug  diphenhydramine drug  acetaminophen drug  ifosfamide drug  mesna  iv  drug  mesna  oral  drug  carboplatin drug  etoposide drug  rituximab pet scan,phase 2
372,chop rituximab augmented gm csf patients previously untreated diffuse large b cell non hodgkin lymphoma,drug  gm csf drug  chop drug  rituximab,phase 2
373,study incb050465 japanese subjects previously treated b cell lymphoma  citadel 111 ,drug  incb050465,phase 1
374,clinical trial evaluate r comp versus r chop newly diagnosed patients non localised diffuse large b cell lymphoma  dlbcl  follicular lymphoma grade iiib,drug  rcomp drug  rchop,phase 2
375,study ofatumumab part scheme reduced intensity conditioning high risk non hodgkin lymphoma b pati,drug  ofatumumab,phase 2
376,ibrutinib stem cell transplant treating patients relapsed refractory diffuse large b cell lymphoma,procedure  autologous bone marrow transplantation procedure  autologous hematopoietic stem cell transplantation drug  carmustine drug  cyclophosphamide drug  cytarabine drug  etoposide drug  ibrutinib laboratory biomarker analysis drug  melphalan pharmacogenomic study placebo,phase 3
377,intergroup randomized trial children adolescents b cell non hodgkin lymphoma b acute leukemia  rituximab evaluation high risk pati,drug  vincristine  cyclophosphamide  methotrexate  doxorubicin  cytarabine  ara c drug  rituximab  vincristine  cyclophosphamide  methotrexate  doxorubicin  cytarabine  ara c,phase 3
378,r ice lenalidomide treating patients first relapse primary refractory diffuse large b cell lymphoma,drug  carboplatin drug  etoposide drug  ifosfamide laboratory biomarker analysis drug  lenalidomide biological  rituximab,phase 1 phase 2
379,multiple fields radiotherapy versus intravenous rituximab treatment indolent cutaneous lymphomas b cell multiple recurrent l,drug  rituximab radiation  multi fields radiotherapi,phase 3
380,addition temozolomide conditioning autologous transplantation relapsed   refractory cns lymphoma,drug  temozolomid,phase 2
381,open label  multicenter  two part  phase 1 study characterize effects moderate cyp3a inhibitor pk tazemetostat  effects tazemetostat pk cyp2c8 cyp2c19 substrates  effect increased gastric ph pk tazemetostat b cell lymphoma advanced solid tumor pati,drug  tazemetostat drug  fluconazole drug  omeprazole drug  repaglinid,phase 1
382,r chop versus r mini ceop elderly patients  65 dlbcl,drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  epirubicin drug  vinblastine drug  rituximab drug  g csf,phase 3
383,impact rituximab patients primary breast diffuse large b cell lymphoma  dlbcl ,nan,nan
384,thalidomide combined r chop newly diagnosed，untreated double expressor diffuse large b cell lymphoma pati,drug  thalidomide combined r chop drug  r chop,phase 3
385,diffuse large b cell lymphoma adult  randomization high dose chemotherapy rituximab chop 14 rituximab,drug  chop rituximab drug  ceep rituximab,applicable
386,rituximab   gm csf patients follicular b cell lymphoma,drug  rituximab drug  gm csf,phase 2
387,pre phase treatment r chop chemotherapy elderly patients newly diagnosed dlbcl,drug  prednisolone 50 mg,phase 2
388,r da edoch versus r ceop90  w upfront auto hsct young patients intermediate high risk dlbcl,drug  r da epoch drug  r da epoch   auto hsct drug  r ceop90 drug  r ceop90   auto hsct,phase 3
389,ibrutinib post stem cell transplantation  sct  double hit b cell lymphoma,drug  ibrutinib,phase 2
390,bendamustine combination ofatumumab  carboplatin etoposide refractory relapsed aggressive b cell lymphoma,drug  bendamustine drug  ofatumumab drug  carboplatin drug  etoposide procedure  ct scan procedure  pet scan genetic  stem cell transplant  stc ,phase 1 phase 2
391,rituximab augmentation following r chop induction chemotherapy extremely elderly patients diffuse large b cell lymphoma,drug  rituximab,phase 2
392,open label  multicenter  phase 1 2 study tazemetostat  ezh2 histone methyl transferase  hmt  inhibitor  single agent subjects adv  solid tumors b cell lymphomas tazemetostat combination prednisolone subjects dlbcl,drug  tazemetostat,phase 1 phase 2
393,gen3013  duobody® cd3xcd20  safety trial patients relapsed  progressive refractory b cell lymphoma,biological  gen3013  duobody® cd3xcd20 ,phase 1 phase 2
394,safety efficacy mak683 adult patients advanced malign,drug  mak683,phase 1 phase 2
395,treatment relapsed low grade follicular lymphoma rituximab  also known rituxan  idec c2b8  idec 102 ,drug  rituximab,phase 3
396,phase ii prospective trial addition rituximab reduced dose chop chemotherapy dlbc l patients aged 65 years ,drug  rituximab  cyclophosphamide  doxorubicin  vincristine  prednison,phase 2
397,dose study doxil dose dense  14 day cdop rituximab regimen patients diffuse large b cell non hodgkin lymphoma  nhl   60 years compromised cardiac status ,drug  doxil drug  cyclophosphamide drug  vincristine drug  prednisone drug  rituximab drug  pegfilgrastim,phase 2
398,study comparing efficiency safety chop cyclophosphamide  hydroxydaunomycin  oncovin  prednisone  versus r chop untreated cd20 cluster differentiation antigen 20  positive dlbcl pati,drug  sct400 plus chop drug  rituximab plus chop,phase 3
399,bendamustine rituximab treatment splenic marginal zone lymphoma,drug  bendamustine rituximab,phase 2
400,chidamide combined r gdp treating patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  chidamide combined r gdp,phase 2
401,clinical research anti cd20 car cells patients refractory relapsed b lymphocyte lymphoma,drug  cd20 car cel,phase 1
402,ebv associated diffuse large b cell lymphoma,clinical pathological data ebv related gzl dlbcl,nan
403,bortezomib plus chop every 2 weeks advanced stage dlbcl,drug  bortezomib drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisolone drug  lenograstim,phase 1 phase 2
404,evaluation car19 cells optimal bridge allogeneic transpl,procedure  leukapheresis drug  cyclophosphamide drug  fludarabine biological  car19 cel,phase 1
405,open label extension study de immunized di leu16 il2 immunocytokine administered patients b cell nhl,drug  di leu16 il2,phase 1 phase 2
406,pembrolizumab combination chemotherapy treating patients previously untreated diffuse large b cell lymphoma grade 3b follicular lymphoma,drug  cyclophosphamide drug  doxorubicin hydrochloride laboratory biomarker analysis biological  pembrolizumab drug  prednisone biological  rituximab drug  vincristine sulf,phase 1
407,metronomic chemotherapy elderly non fit patients aggressive b cell lymphoma,drug  prednisone drug  vinorelbine drug  etoposide drug  cyclophosphamide drug  rituximab,phase 2
408,avelumab  utomilumab  rituximab  ibrutinib  combination chemotherapy treating patients relapsed refractory diffuse large b cell lymphoma mantle cell lymphoma,procedure  autologous hematopoietic stem cell transplantation drug  avelumab drug  carboplatin drug  etoposide phosphate drug  ibrutinib drug  ifosfamide laboratory biomarker analysis biological  rituximab biological  utomilumab,phase 1
409,phase ii study de immunized di leu16 il2 immunocytokine administered subcutaneously patients b cell nhl,drug  0 5 mg m2 di leu16 il2 drug  1 0 mg m2 di leu16 il2 drug  2 0 mg m2 di leu16 il2 drug  4 0 mg m2 di leu16 il2 drug  6 0 mg m2 di leu16 il2 drug  8 0 mg m2 di leu16 il2 drug  10 0 mg m2 di leu16 il2 drug  50mg m2 rituximab,phase 1 phase 2
410,tailored prednisone reduction preventing hyperglycemia participants b cell non hodgkin lymphoma receiving combination chemotherapy treat,drug  cyclophosphamide drug  doxorubicin hydrochloride laboratory biomarker analysis drug  prednisone quality life assessment questionnaire administration biological  rituximab drug  vincristine sulf,phase 2
411,phase study evaluate safety  tolerability adults lymphoma,drug  medi 538,phase 1
412,geriatric assessments elderly diffuse large b cell lymphoma patients 2  geriad2 ,nan,nan
413,geriatric assessments elderly diffuse large b cell lymphoma,nan,nan
414,interventional study pentostatin  cyclophosphamide rituximab indolent b cell non hodgkin lymphoma  b nhl ,drug  cyclophosphamide  pentostatin  rituximab,phase 2
415,vaccine therapy treating patients recurrent b cell lymphoma,biological  plasmid dna vaccine therapy flow cytometry immunoenzyme techniqu,phase 1
416,study evaluate safety efficacy blinatumomab subjects relapsed refractory  r r  aggressive b cell nhl,drug  blinatumomab drug  investigator choice chemotherapi,phase 2 phase 3
417,cd19 targeted chimeric antigen receptor cells b cell lymphoma,biological  cd19 targeted chimeric antigen receptor cel,phase 1 phase 2
418,nivolumab without varlilumab treating patients relapsed refractory aggressive b cell lymphoma,laboratory biomarker analysis biological  nivolumab pharmacological study drug  varlilumab,phase 2
419,bi 1206 anti cd20 antibody patients cd32b positive b cell lymphoma leukaemia,biological  bi 1206 single agent dose escalation phase biological  bi 1206 single agent expansion phase biological  combination bi 1206 rituximab,phase 1 phase 2
420,study evaluation efficacy safety sh l 749 indolent b cell non hodgkin lymphoma,drug  zevalin  sh l 749   bay86 5128 ,phase 2
421,90y ibritumomab tiuxetan consolidation 6th r chop chemotherapy patients bulky diffuse large b cell lymphoma,drug  ibritumomab tiuxetan  zevalin ,phase 2
422,ultra low dose 4 gy orbital radiation definitive therapy indolent b cell lymphoma,radiation  radiation therapi,phase 2
423,pembrolizumab vorinostat treating patients relapsed refractory diffuse large b cell lymphoma  follicular lymphoma  hodgkin lymphoma,laboratory biomarker analysis biological  pembrolizumab drug  vorinostat,phase 1
424,b001 patients cd20 positive b cell non hodgkin lymphoma,biological  b001,phase 1
425,ofatumumab older patients untreated low intermediate risk indolent b cell lymphoma,drug  ofatumumab,phase 2
426,study actr707 combination rituximab subjects relapsed refractory b cell lymphoma,biological  actr707 biological  rituximab,phase 1
427,study actr087 subjects relapsed refractory b cell lymphoma,biological  actr087 biological  rituximab,phase 1
428,car cd19 cd28 zeta 2a icasp9 il15 transduced cord blood nk cells  high dose chemotherapy  stem cell transplant treating participants b cell lymphoma,procedure  autologous hematopoietic stem cell transplantation drug  carmustine drug  cytarabine drug  etoposide biological  filgrastim drug  melphalan biological  rituximab biological  umbilical cord blood derived natural killer cel,phase 1 phase 2
429,lenalidomide combination chemotherapy  da epoch r  treating patients myc associated b cell lymphoma,drug  lenalidomide drug  etoposide drug  prednisone drug  vincristine sulfate drug  doxorubicin hydrochloride drug  cyclophosphamide biological  rituximab quality life assessment laboratory biomarker analysi,phase 1 phase 2
430,eradication helicobacter pylori management stage ie   iie 1 primary low grade b cell lymphoma maltoma,omeprazole  amoxicillin  clarithromycin,applicable
431,novel combination therapy treatment relapsed refractory aggressive b cell lymphoma,drug  ibrutinib drug  rituximab drug  gemcitabine drug  dexamethasone drug  cisplatin drug  mesna drug  cyclophosphamide drug  etoposide drug  g csf,phase 2
432,study itacitinib  incb039110  combination ibrutinib subjects relapsed refractory diffuse large b cell lymphoma,drug  itacitinib drug  ibrutinib,phase 1 phase 2
433,rituximab  bendamustine melphalan chemo immunotherapy followed reinfusion one stem cell treatment b cell lymphoma elderly pati,drug  rituximab drug  bendamustine drug  melphalan procedure  autologous stem cell transplantation  asct ,phase 1 phase 2
434,phase ii study lenalidomide obinutuzumab chop diffuse large b cell lymphoma,drug  lenalidomide drug  obinutuzumab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 1 phase 2
435,targeted intensification zbeam autologous stem cell transplantation patients high grade b cell lymphoma,drug  zbeam  zevalin  bcnu  etoposide  aracytine  melphalan  procedure  asct drug  rituximab,phase 2
436,efficacy safety study lenalidomide plus r chop chemotherapy versus placebo plus r chop chemotherapy untreated abc type diffuse large b cell lymphoma,drug  lenalidomide drug  placebo drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  prednisone drug  vincristin,phase 3
437,high dose chemotherapy asct consolidating conventional chemotherapy primary cns lymphoma,drug  arm fortecortin® etopophos® ifo cell® carbo cell®  drug  arm b  tepadina® carmubris® busilvex® ,phase 3
438,phase 2 safety efficacy study incb050465 subjects relapsed refractory diffuse large b cell lymphoma  citadel 202 ,drug  incb050465,phase 2
439,safety study sgn cd19b patients b cell non hodgkin lymphoma,drug  sgn cd19b,phase 1
440,r dose adjusted  da    epoch 21 versus r modified non hodgkin lymphoma  nhl  berlin frankfurt munster  bfm  90 program  mnhl bfm 90  autologous stem cells transplantation  auto sct  dlbcl poor prognosi,drug  r da epoch 21 drug  r da epoch 21   auto sct drug  r mnhl bfm 90 drug  r mnhl bfm 90   auto sct,phase 3
441,rituximab maintenance therapy marginal zone b cell lymphoma  mzl ,drug  rituximab,phase 2
442,phase ii study cd30 positive diffuse large b cell lymphoma patients refractory first line chemotherapy first relap,combination product  r dhap drug  brentuximab vedotin,phase 1 phase 2
443,study radiolabeled monoclonal antibody anti b1 treatment b cell lymphomas extended study determine safety efficacy coulter clone® 131iodine b1 radioimmunotherapy advanced non hodgkin lymphoma,biological  radiolabeled monoclonal antibody anti b1 treatment b cell lymphomas  tositumomab iodine 131 tositumomab ,phase 1
444,safety tolerability study pci 32765 b cell lymphoma chronic lymphocytic leukemia,drug  pci 32765,phase 2
445,study durvalumab combination r chop lenalidomide plus r chop previously untreated high risk diffuse large b cell lymphoma,drug  durvalumab drug  rituximab drug  doxorubicin drug  vincristine drug  cyclophosphamide drug  prednisone drug  lenalidomid,phase 2
446,early therapy pet first line treatment diffuse large b cell lymphoma stage iib iv,procedure  pet scan,nan
447,combination chemotherapy without autologous stem cell transplant treating patients central nervous system b cell lymphoma,drug  carmustine drug  cytarabine drug  etoposide drug  thiotepa procedure  stem cell transplant drug  g csf,phase 2
448,phase ii palbociclib  ibrutinib mantle cell lymphoma,drug  palbociclib drug  ibrutinib,phase 2
449,combination chemotherapy rituximab treating patients primary mediastinal diffuse large b cell lymphoma,biological  bleomycin sulfate biological  filgrastim biological  rituximab drug  cyclophosphamide drug  cytarabine drug  doxorubicin hydrochloride drug  etoposide phosphate drug  ifosfamide drug  methotrexate drug  prednisolone drug  prednisone drug  vincristine sulfate drug  vindesin,applicable
450,open label  multi center  two part  ph1 study characterize pks intravenous micro dose 14c  tazemetostat  epz 6438  adme oral  14c  labeled dose tazemetostat subjects b cell lymphomas adv solid tumor,drug  tazemetostat 14c  tazemetostat,phase 1
451,study patients primary breast diffuse large b cell lymphoma,drug  rituximab procedure  prophylactic intrathecal chemotherapi,phase 2
452,smart start  study rituximab  lenalidomide  ibrutinib combined chemotherapy patients high risk diffuse large b cell lymphoma,drug  rituximab drug  ibrutinib drug  lenalidomide drug  etoposide drug  prednisone drug  vincristine drug  cyclophosphamide drug  doxorubicin,phase 2
453,phase ii trial vr chop lymphoma pati,drug  bortezomib biological  rituximab drug  doxorubicin drug  cyclophosphamide drug  vincristine drug  prednison,phase 1 phase 2
454,btk inhibitor b cell malign,drug  m7583,phase 1 phase 2
455,combination oral fludarabine  mitoxantrone und rituximab induction therapy rituximab maintenance therapy follicular b cell lymphoma,drug  rituximab,phase 2
456,rituximab combination chemotherapy without bleomycin sulfate treating patients primary mediastinal large b cell lymphoma,biological  bleomycin sulfate biological  rituximab drug  epoch regimen drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide drug  prednisone drug  vincristine sulf,phase 2
457,efficacy safety study fostamatinib tablets treat b cell lymphoma,drug  fostamatinib,phase 1 phase 2
458,lenalidomide combined vorinostat gemcitabine busulfan melphalan autologous stem cell transplantation diffuse large b cell lymphoma abc subtyp,drug  lenalidomide drug  vorinostat drug  gemcitabine drug  busulfan drug  melphalan drug  rituximab drug  dexamethasone drug  caphosol drug  glutamine drug  pyridoxine drug  enoxaparin procedure  stem cell transplant drug  palifermin,phase 1 phase 2
459,phase ib study belinostat rdhap chemotherapy  dexamethasone  cytarabine  cisplatinum  adults relapsed refractory diffuse large b cell lymphoma,drug  belinostat drug  rituximab drug  cisplatin drug  cytarabine drug  dexamethasone drug  ciprofloxacin drug  fluconazol,phase 1
460,treatment degenerative neoplastic diseases rituximab,biological  rituximab,phase 2 phase 3
461,low dose radiotherapy diffuse large b cell lymphoma,radiation  low dose radiotherapi,phase 2
462,pilot project creation diffuse large b cell lymphoma  dlbcl  response prediction model,drug  18f fluorodeoxyglucose procedure  fdg pet ct imaging procedure  blood draw,applicable
463,beam vs  90 yttrium ibritumomab tiuxetan  zevalin®  beam asct relapsed dlbcl,radiation  90 yttrium ibritumomab tiuxetan drug  carmustine drug  etoposide drug  cytarabine drug  melphalan procedure  autologous hematopoietic stem cell transplant biological  rituximab,phase 3
464,adam17 inhibitor  rituximab auto hct dlbcl,drug  rituximab drug  incb7839,phase 1 phase 2
465,18f fdg pet ct based prognostic model predicting outcome patients diffuse large b cell lymphoma,device  18f fdg pet ct,applicable
466,study evaluating safety efficacy c car011 subjects b nhl,biological  c car011,phase 1
467,study recombinant human mouse chimeric anti cd20 monoclonal antibody treat non hodgkin lymphoma,drug  chop combined cmab304 drug  chop  cmab304,phase 3
468,rituximab gm csf treating patients newly diagnosed follicular b cell lymphoma,biological  rituximab biological  sargramostim  gm csf ,phase 2
469,rituximab  gemcitabine oxaliplatin  r gemox  refractory relapsed b cell lymphoma,drug  gemcitabine oxaliplatin plus rituximab  r gemox ,phase 2
470,cytoplasmic activated pd 1 car cells refractory relapsed b cell lymphoma,drug  car19 cells carrying cytoplasmic activated pd 1,phase 1
471,phase clinical trial assess safety syb l 0501 combination rituximab patients aggressive b cell non hodgkin lymphoma,drug  syb l 0501 drug  rituximab,phase 1
472,azd1152 diffuse large b cell lymphoma,drug  azd1152,phase 1 phase 2
473,interim fdg pet ct diffuse large b cell lymphoma  dlbcl  pati,early interim fdg pet ct 1 cycle r chop,applicable
474,high dose 90 ibritumomab tiuxetan added reduced intensity allogeneic stem cell transplant regimen relapsed refractory aggressive b cell lymphoma,procedure  allogeneic hematopoietic stem cell transplantation drug  cyclosporine drug  fludarabine phosphate radiation  indium 111 ibritumomab tiuxetan drug  mycophenolate mofetil pharmacological study biological  rituximab radiation  total body irradiation radiation  yttrium 90 ibritumomab tiuxetan,phase 2
475,dpx survivac checkpoint inhibitor dlbcl,biological  dpx survivac biological  pembrolizumab drug  cyclophosphamide 50mg,phase 2
476,phase ib ii combination acalabrutinib r chop patient diffuse large b cell lymphoma  dlbcl ,drug  acalabrutinib,phase 2
477,rituximab  bendamustine hydrochloride  lenalidomide treating patients aggressive b cell lymphoma,biological  rituximab drug  bendamustine hydrochloride drug  lenalidomid,phase 1 phase 2
478,brentuximab vedotin lenalidomide relapsed refractory diffuse large b cell lymphoma,drug  brentuximab vedotin drug  lenalidomid,phase 1
479,combination pembrolizumab tgr 1202 patients relapsed refractory cll b cell nhl,drug  tgr 1202 drug  pembrolizumab,phase 1
480,study bruton tyrosine kinase inhibitor  pci 32765  ibrutinib   combination rituximab  cyclophosphamide  doxorubicin  vincristine  prednisone patients newly diagnosed non germinal center b cell subtype diffuse large b cell lymphoma,drug  ibrutinib drug  placebo drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone  equivalent ,phase 3
481,evaluating 18f fdg pet ct liver suvmax based criteria prognosis patients diffuse large b cell lymphoma,device  18f fdg pet ct,applicable
482,rituximab combination chemotherapy treating older patients previously untreated b cell lymphoma,biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate pharmacological study radiation  radiation therapi,phase 2
483,study tazemetostat newly diagnosed diffuse large b cell lymphoma patients treated chemiotherapi,drug  tazemetostat drug  rituximab drug  cyclophosphamide drug  vincristine drug  doxorubicin drug  prednisolon,phase 1 phase 2
484,pembrolizumab asct hodgkin lymphoma  dlbcl nhl,drug  pembrolizumab,phase 2
485,cinobufacini tablets combined chemotherapeutic protocol treatment diffuse large b cell lymphoma,drug  vindesine drug  cyclophosphamide drug  epirubicin drug  prednisone tablets drug  cinobufacini tablets drug  rituximab,phase 2 phase 3
486,phase ii copanlisib relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  copanlisib  bay80 6946 ,phase 2
487,adjuvant low dose total body irradiation elderly patients diffuse large b cell lymphoma,radiation  low dose total body irradi,phase 2
488,chidamide combined clad gem bu autosct r r diffuse large b cell lymphoma,drug  chidamide drug  cladribine drug  gemcitabine drug  busulfan procedure  autologous hematopoietic stem cell transplant,phase 2
489,lenalidomide  rituximab  combination chemotherapy treating patients newly diagnosed stage ii  stage iii  stage iv diffuse large cell follicular b cell lymphoma,biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  lenalidomide drug  prednisone drug  vincristine sulfate genetic  polymorphism analysis laboratory biomarker analysi,phase 1 phase 2
490,study trph 222 patients relapsed refractory b cell lymphoma,drug  trph 222,phase 1
491,efficacy safety study r chop vs bortezomib r cap young patients diffuse large b cell lymphoma poor ipi ,drug  bortezomib drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  prednisone drug  vincristin,phase 2
492,randomised evaluation molecular guided therapy diffuse large b cell lymphoma bortezomib,drug  intravenous drug  bortezomib,phase 3
493,nm il 12  rhuil‐12  relapsed refractory diffuse large b  cell lymphoma  dlbcl  undergoing salvage chemotherapi,biological  nm il 12,phase 2
494,r chop versus r cdop first line treatment elderly patients diffuse large b cell lymphoma,drug  pegylated liposomal doxorubicin drug  doxorubicin drug  rituximab drug  cyclophophamide drug  vincristine drug  prednison,phase 3
495,study chidamide single agent treatment patients relapse refractory b nhl,drug  chidamid,phase 2
496,study evaluating efficacy safety car recurrent refractory diffuse large b cell lymphoma,biological  cd19 targeted car cel,applicable
497,comparison hd chemotherapy followed auto transplant r chop high risk patients dlbcl ,drug  rituximab hds drug  rituximab chop,phase 3
498,tazemetostat treating patients metastatic unresectable solid tumors b cell lymphomas liver dysfunct,laboratory biomarker analysis pharmacological study drug  tazemetostat,phase 1
499,rituximab combination chemotherapy combined yttrium 90 ibritumomab tiuxetan treating older patients previously untreated b cell lymphoma,biological  darbepoetin alfa biological  filgrastim biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate radiation  indium 111 ibritumomab tiuxetan radiation  yttrium 90 ibritumomab tiuxetan,phase 2
500,study comparing efficacy safety chop r chop untreated cd20 positive diffuse large b cell lymphoma pati,drug  ibi301 plus chop drug  rituximab plus chop,phase 3
501,30gy versus 40gy involved field radiotherapy localized diffuse large b cell lymphoma achieving cr chemotherapi,radiation  3d crt based involved field radiotherapi,phase 3
502,quilt 3 002  alt 803 patients relapse refractory inhl conjunction rituximab,biological  rituximab biological  alt 803,phase 1 phase 2
503,bucy vp 16 vs bucy conditioning regimen dlbcl undergoing auto hsct,drug  busulfan  bu  drug  cyclophosphamide  cy  drug  etoposide  vp 16 ,phase 2 phase 3
504,novel combinations cc 122  cc 223  cc 292  rituximab diffuse large b cell lymphoma follicular lymphoma,drug  cc 122 drug  cc 223 drug  rituximab drug  cc 292,phase 1
505,efficacy safety ibrutinib patients cll indolent b cell lymphomas chronic hepatitis b virus carriers occult hepatitis b virus carri,drug  ibrutinib,phase 3
506,study ro7082859 combination rituximab obinutuzumab plus chemotherapy participants non hodgkin lymphoma,drug  ro7082859 drug  obinutuzumab  g  drug  rituximab  r  drug  tocilizumab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 1
507,s1001 pet directed therapy treating patients limited stage diffuse large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate r chop regimen laboratory biomarker analysis radiation  fludeoxyglucose f 18 radiation  selective external radiation therapy radiation  yttrium 90 ibritumomab tiuxetan,phase 2
508,s9704 s0014 s0313a studying genes samples patients limited advanced diffuse large b cell lymphoma,genetic  rna analysis genetic  gene expression analysis immunohistochemistry staining method laboratory biomarker analysi,nan
509,study et190l1 artemis™ cells relapsed refractory cd19  non hodgkin lymphoma,biological  et190l1 artemis™ cel,phase 1
510,nab paclitaxel rituximab coated nanoparticle ar160 treating patients relapsed refractory b cell non hodgkin lymphoma,laboratory biomarker analysis drug  nab paclitaxel rituximab coated nanoparticle ar160 pharmacological studi,phase 1
511,trial prospective observational study newly diagnosed diffuse large b cell primary breast lymphoma,nan,nan
512,phase 1  open label trial oral azacitidine  cc 486  plus rchop subjects large b cell lymphoma follicular lymphoma transformed lymphoma,drug  oral azacitidine drug  rituximab drug  cyclophosphamide drug  vincristine drug  prednison,phase 1
513,oral azacitidine plus salvage chemotherapy relapsed refractory diffuse large b cell lymphoma,drug  oral azacitidine drug  r ic,phase 1
514,r bl 04 versus r  da  epoch autologous stem cells transplantation patients high grade b cell lymphoma double hit  hgbl dh  high grade b cell lymphoma otherwise specified  hgbl nos ,drug  r da epoch 21 drug  r bl 04 drug  r da epoch 21   auto sct drug  r bl 04   auto sct,phase 3
515,everolimus  rituximab  combination chemotherapy treating patients newly diagnosed untreated diffuse large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  everolimus drug  prednisone drug  vincristine sulf,phase 1
516,selumetinib treating patients relapsed refractory diffuse large b cell lymphoma,laboratory biomarker analysis drug  selumetinib,phase 2
517,liquid biopsy mature b cell tumor,diagnostic test  liquid biopsi,nan
518,phase 2 intratumoral injection pf 3512676 plus local radiation low grade b cell lymphoma,drug  pf 3512676 radiation  local radiotherapi,phase 2
519,comparison pixantrone   rituximab gemcitabine   rituximab patients aggressive b cell non hodgkin lymphoma follicular grade 3 lymphoma relapsed therapy eligible stem cell transpl,drug  pixantrone   rituximab drug  gemcitabine   rituximab,phase 3
520,study mabthera  rituximab  addition regularly prescribed chemotherapy patients untreated mantle cell lymphoma ,drug  cyclophosphamide drug  fludarabine drug  mitoxantrone drug  rituximab,phase 2
521,study subcutaneous versus intravenous mabthera rituxan  rituximab  combination chop chemotherapy patients previously untreated cd20 positive diffuse large b cell lymphoma,drug  chop drug  rituximab  mabthera rituxan ,phase 3
522,study blood tissue samples patients aggressive non hodgkin b cell lymphoma hodgkin lymphoma,genetic  polymerase chain reaction laboratory biomarker analysi,nan
523,study polatuzumab vedotin  dcds4501a  combination rituximab obinutuzumab plus bendamustine participants relapsed refractory follicular diffuse large b cell lymphoma,drug  bendamustine drug  obinutuzumab drug  polatuzumab vedotin  liquid  drug  rituximab drug  polatuzumab vedotin  lyophilized ,phase 1 phase 2
524,feasibility study gallium 68 citrate pet detect aberrant myc protein expression diffuse large b cell lymphoma,radiation  gallium citr,applicable
525,denintuzumab mafodotin  sgn cd19a  combined rchop rchp versus rchop alone diffuse large b cell lymphoma follicular lymphoma,drug  denintuzumab mafodotin drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 2
526,bortezomib  doxorubicin hydrochloride liposome  rituximab treating patients diffuse large b cell lymphoma relapsed responded treat,biological  rituximab drug  bortezomib drug  pegylated liposomal doxorubicin hydrochloride genetic  gene expression analysis genetic  polymerase chain reaction genetic  polymorphism analysis genetic  proteomic profiling flow cytometry laboratory biomarker analysi,phase 2
527,biomarkers patients diffuse large b cell lymphoma treated combination chemotherapy without rituximab,genetic  gene expression analysis laboratory biomarker analysi,nan
528,radiation dose optimization diffuse large b  cell lymphoma ,radiation  standard arm radiation  experimental arm,phase 3
529,carfilzomib consolidation therapy autologous stem cell transplantation  asct  mantle cell lymphoma  mcl   cell lymphoma  tcl   diffuse large b cell lymphoma  dlbcl ,drug  carfilzomib drug  dexamethason,phase 1
530,escalating dose study subjects relapsed refractory b cell non hodgkin lymphoma  chronic lymphocytic leukemia  waldenstrom macroglobulinemia,drug  avl 292,phase 1
531,dose escalation study oral administration 55746 patients chronic lymphocytic leukaemia b cell non hodgkin lymphoma,drug  55746,phase 1
532,clofarabine relapsed refractory cell b cell non hodgkin lymphoma  nhl ,drug  clofarabin,phase 1 phase 2
533,study nivolumab patients relapsed refractory diffuse large b cell lymphoma  dlbcl  either failed eligible autologous stem cell transplant  checkmate 139 ,drug  nivolumab,phase 2
534,phase 2 study velcade™ subjects relapsed refractory follicular b cell lymphoma,drug  bortezomib,phase 2
535,ofatumumab versus rituximab salvage chemoimmunotherapy followed autologous stem cell transplant relapsed refractory diffuse large b cell lymphoma,drug  ofatumumab   dhap drug  rituximab   dhap,phase 3
536,aflibercept standard chemotherapy  r chop  first line non hodgkin b cell lymphoma,drug  aflibercept,phase 1
537,flavopiridol treat relapsed mantle cell lymphoma diffuse large b cell lymphoma,drug  flavopiridol,phase 1 phase 2
538,r acvbp versus r chop patients aged 60 65 diffuse large b cell lymphoma,drug  rituximab drug  doxorubicin drug  cyclophosphamide drug  vindesine drug  bleomycin drug  prednisone drug  vincristin,phase 3
539,study intensive consolidation stem cell mobilization therapy followed autologous stem cell transplantation high risk patients relapsed refractory diffuse large b cell lymphoma,drug  ofatumumab drug  etoposide drug  cytarabin,phase 2
540,acvbp versus acvbp plus rituximab low risk localized diffuse large b cell lymphoma,drug  rituximab,phase 3
541,gemcitabine hydrochloride  cyclophosphamide  vincristine sulfate  prednisolone  rituximab treating patients newly diagnosed diffuse large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  gemcitabine hydrochloride drug  prednisolone drug  vincristine sulf,phase 2
542,se methyl seleno l cysteine  rituximab  ifosfamide  carboplatin  etoposide treating patients diffuse large b cell lymphoma relapsed responded treat,biological  filgrastim biological  rituximab dietary supplement  se methyl seleno l cysteine drug  carboplatin drug  etoposide drug  ifosfamide laboratory biomarker analysis pharmacological studi,phase 1 phase 2
543,acvbp plus rituximab patients aged 18 59 years high risk diffuse large b cell lymphoma,drug  rituximab drug  doxorubicin drug  cyclophosphamide procedure  autologous stem cell transplant,phase 2
544,study iodine 131 anti b1 antibody 1st 2nd relapsed indolent b cell lymphomas b cell lymphomas transformed aggressive histolog,biological  tositumomab iodine 131 tositumomab  anti b1 antibody ,phase 2
545,bortezomib treating patients diffuse large b cell lymphoma refractory chemotherapi,drug  bortezomib,phase 2
546,r ice versus r dhap patients aged 18 65 relapse diffuse large b cell lymphoma,drug  rituximab drug  etoposide drug  carboplatine drug  ifosfamide   mesna drug  cisplatine drug  cytosine arabinoside drug  dexamethasone procedure  autologous stem cell transplantation drug  bcnu drug  cytarabine drug  melphalan,phase 3
547,flt pet ct vs fdg pet ct therapy monitoring diffuse large b cell lymphoma,diagnostic test  flt pet ct diagnostic test  fdg pet ct drug  flt,applicable
548,monoclonal antibody therapy combination chemotherapy treating patients stage ii  stage iii  stage iv diffuse large b cell lymphoma,biological  epratuzumab biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 2
549,study biomarkers using tissue samples older patients diffuse large b cell lymphoma treated combination chemotherapy without rituximab clinical trial ecog e4494,laboratory biomarker analysi,nan
550,acvbp plus rituximab versus chop plus rituximab patients diffuse large b cell lymphoma age adjusted ipi 1,drug  rituximab drug  doxorubicin drug  cyclophosphamid,phase 3
551,study evaluating safety pharmacokinetics jcar017 b cell non hodgkin lymphoma  transcend nhl 001 ,biological  jcar017  lisocabtagene maraleucel  single dose schedule biological  jcar017  lisocabtagene maraleucel  2 dose schedul,phase 1
552,acvbp followed asct patients bcl 2 positive diffuse large b cell lymphoma,drug  doxorubicin drug  cyclophosphamide procedure  autologous stem cell transplant,phase 2 phase 3
553,dosimetry biodistribution 18f  fludarabine lymphoid malign,18f    fludarabine pet ct,phase 1
554,dosimetry validation study 131iodine anti b1  murine  radioimmunotherapy chemotherapy refractory low grade b cell lymphomas low grade lymphomas transformed higher grade histolog,biological  tositumomab  anti b1 antibody  iodine 131 tositumomab,phase 2
555,comparison study rituximab plus sargramostim rituximab alone relapsed follicular b cell lymphoma  form non hodgkin lymphoma,drug  sargramostim  leukine  drug  rituximab,phase 2
556,trial patients diffuse large b cell lymphoma comparing pixantrone doxorubicin,drug  cpop r drug  chop r,phase 2
557,r chop 14 versus r chop 21 darbepoetin alpha patients aged 60 80 years diffuse large b cell lymphoma,drug  darbepoetin alfa,phase 3
558,ifosfamide carboplatin etoposide rituxan followed zevalin relapsed refractory intermediate grade b cell lymphoma,drug  ifosfamide drug  carboplatin drug  etoposide drug  rituximab drug  90y zevalin,phase 2
559,pet scans patients diffuse large b cell lymphoma receiving rituximab  cyclophosphamide  doxorubicin  vincristine  prednison,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate procedure  positron emission tomographi,applicable
560,chidamide patients relapse refractory diffuse large b cell lymphoma follicular lymphoma,drug  chidamid,phase 2
561,study sgn 40 patients relapsed diffuse large b cell lymphoma,drug  sgn 40,phase 2
562,trivalent baculovirus expressed influenza ha vaccine adults non hodgkin b cell lymphoma,biological  trivalent inactivated influenza vaccine biological  trivalent baculovirus expressed influenza ha vaccin,phase 2
563,gm csf without vaccine therapy combination chemotherapy rituximab first line therapy treating patients stage ii  stage iii  stage iv diffuse large b cell lymphoma,drug  autologous immunoglobulin idiotype klh conjugate vaccine drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  rituximab drug  sargramostim drug  vincristine procedure  intervention procedure procedure  antibody therapy procedure  biological therapy procedure  chemotherapy procedure  colony stimulating factor therapy procedure  cytokine therapy procedure  monoclonal antibody therapy procedure  non specific immune modulator therapy procedure  therapeutic procedure procedure  tumor cell derivative vaccine procedure  vaccine therapi,phase 3
564,axicabtagene ciloleucel expanded access studi,biological  axicabtagene ciloleucel,nan
565,safety antitumor activity study loncastuximab tesirine durvalumab diffuse large b cell  mantle cell  follicular lymphoma,drug  loncastuximab tesirine durvalumab,phase 1
566,phase safety  pk pd study kw 2478 patients multiple myeloma  chronic lymphocytic leukaemia b cell non hodgkin lymphoma,drug  kw 2478,phase 1
567,ofatumumab initial systemic treatment indolent b cell lymphoma,drug  ofatumumab,phase 2
568,oblimersen  rituximab  cyclophosphamide  doxorubicin  vincristine  prednisone treating patients stage ii  stage iii  stage iv diffuse large b cell lymphoma,biological  oblimersen sodium biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 1
569,dose augmented rituximab ice pts primary refractory poor risk relapsed aggressive b cell nhl,drug  rituximab  ifosfamide  carboplatin  vp 16  mesna  g csf  stem cell transpl,phase 2
570,carfilzomib  rituximab  combination chemotherapy treating patients diffuse large b cell lymphoma,drug  carfilzomib biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone laboratory biomarker analysi,phase 1 phase 2
571,phase iia study redirected autologous cells engineered contain anti cd19 attached tcrz 4 signaling domains patients chemotherapy relapsed refractory cd19  lymphoma,biological  cart 19,phase 2
572,rituximab  romidepsin  lenalidomide treating patients recurrent refractory b cell non hodgkin lymphoma,biological  rituximab drug  lenalidomide drug  romidepsin laboratory biomarker analysi,phase 1 phase 2
573,vorinostat  cladribine  rituximab treating patients mantle cell lymphoma  relapsed chronic lymphocytic leukemia  relapsed b cell non hodgkin lymphoma,drug  cladribine laboratory biomarker analysis biological  rituximab drug  vorinostat,phase 2
574,study obinutuzumab combination idasanutlin venetoclax participants relapsed refractory  r r  follicular lymphoma  fl  rituximab combination idasanutlin venetoclax participants r r diffuse large b cell lymphoma  dlbcl ,drug  idasanutlin drug  obinutuzumab drug  venetoclax drug  rituximab,phase 1 phase 2
575,sar3419 administered weekly patients relapsed refractory cd19 positive b cell non hodgkin lymphoma,drug  sar3419,phase 1
576,alisertib without rituximab treating patients relapsed refractory b cell non hodgkin lymphoma,drug  alisertib biological  rituximab laboratory biomarker analysi,phase 2
577,study bruton tyrosine kinase inhibitor subjects relapsed refractory marginal zone lymphoma,drug  ibrutinib,phase 2
578,vorinostat combination chemotherapy rituximab treating patients hiv related diffuse large b cell non hodgkin lymphoma aggressive b cell lymphoma,drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide laboratory biomarker analysis pharmacological study drug  prednisone biological  rituximab drug  vincristine sulfate drug  vorinostat,phase 1 phase 2
579,ofatumumab patients relapsed progressive diffused large b cell lymphoma  dlbcl  ineligible relapse progression transpl,drug  ofatumumab,phase 2
580,phase ii study brentuximab vedotin combination multi agent chemotherapy front line treatment patients cd30 positive primary mediastinal large b cell  diffuse large b cell  grey zone lymphoma,drug  brentuximab vedotin,phase 1 phase 2
581,safety feasibility study combination state art chemoimmunotherapy  intensive central nervous system prophylaxis scrotal irradiation treat primary diffuse large b cell lymphoma testi,drug  rituximab  cyclophosphamide  doxorubicin  vincristine  prednisolone  liposomal cytarabine  methotrex,phase 2
582,combination therapy using lenalidomide  revlimid   low dose dexamethasone rituximab treatment rituximab resistant  non aggressive b cell lymphoma,drug  lenalidomide low dose dexamethasone plus rituximab drug  lenalidomide   rituximab,phase 2
583,safety pharmacology study atezolizumab  mpdl3280a  administered obinutuzumab tazemetostat participants relapsed refractory follicular lymphoma diffuse large b cell lymphoma,drug  atezolizumab drug  obinutuzumab drug  tazemetostat,phase 1
584,cyclophosphamide alemtuzumab lymphoma,drug  cyclophosphamide drug  alemtuzumab,phase 1
585,lenalidomide r chop b cell lymphoma,drug  lenalidomide r chop,phase 1 phase 2
586,cci 779 treating patients recurrent refractory b cell non hodgkin lymphoma chronic lymphocytic leukemia,drug  temsirolimu,phase 2
587,detection quant differences hodgkin lymphoma diffuse large b cell lymphoma using positron emission tomography computed tomography  pet ct ,radiation  fludeoxyglucose f18 procedure  computed tomography procedure  positron emission tomographi,applicable
588,study evaluate safety  efficacy pharmacokinetics rituximab  mabthera rituxan  participants diffuse large b cell lymphoma  dlbcl  follicular lymphoma  fl ,drug  rituximab drug  cyclophosphamide drug  vincristine drug  doxorubicin drug  prednisone drug  bendamustin,phase 3
589,bueam conditioning autologous stem cell transplantation  asct  treat diffuse large b cell lymphoma  dlcbl ,drug  busulfan  etoposide  cytarabine  melphalan,phase 2
590,rituximab combination chemotherapy treating patients previously untreated high  high intermediate risk diffuse large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone laboratory biomarker analysis pharmacological studi,phase 2
591,fenretinide rituximab treating patients b cell non hodgkin lymphoma,drug  fenretinide drug  rituximab,phase 1 phase 2
592,study evaluating safety efficacy obinutuzumab  polatuzumab vedotin  pola   atezolizumab  atezo  participants relapsed refractory follicular lymphoma  fl  rituximab  atezo  pola participants relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  atezolizumab  tecentriq  drug  obinutuzumab drug  polatuzumab vedotin drug  rituximab,phase 1 phase 2
593,study velcade rituximab patients relapsed refractory b cell non hodgkin lymphoma,drug  bortezomib   rituximab drug  rituximab,phase 3
594,jcar014 durvalumab treating patients relapsed refractory b cell non hodgkin lymphoma,biological  autologous anti cd19car 4 1bb cd3zeta egfrt expressing cd4  cd8  central memory lymphocytes jcar014 drug  cyclophosphamide biological  durvalumab drug  fludarabine phosphate laboratory biomarker analysis pharmacological studi,phase 1
595,study busulfan  etoposide  cytarabine  melphalan  bueam  conditioning autologous stem cell transplantation  asct  treat b cell lymphoma except diffuse large b cell lymphoma,drug  busulfan  etoposide  cytarabine  melphalan,phase 2
596,pilot study anti cd20 car engineered cells patients chemotherapy resistant refractory cd20  lymphoma,biological  cart20,phase 1 phase 2
597,phase ii study pembrolizumab patients relapsed refractory extranodal nk cell lymphoma  enktl   nasal type ebv associated diffuse large b cell lymphomas  ebv dlbcl ,drug  pembrolizumab,phase 1 phase 2
598,vorinostat  rituximab  combination chemotherapy treating patients newly diagnosed stage ii  stage iii  stage iv diffuse large b cell lymphoma,drug  cyclophosphamide drug  doxorubicin hydrochloride laboratory biomarker analysis drug  prednisone biological  rituximab drug  vincristine sulfate drug  vorinostat,phase 1 phase 2
599,study oral ly317615 relapsed refractory diffuse large b cell lymphomas ,drug  ly317615,phase 2
600,oblimersen sodium combination chemotherapy treating patients newly diagnosed stage stage ii  stage iii  stage iv diffuse large b cell lymphoma,biological  oblimersen sodium biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone procedure  biopsy genetic  microarray analysis immunohistochemistry staining method genetic  gene expression analysis genetic  cytogenetic analysi,applicable
601,sunitinib treating patients relapsed refractory diffuse mediastinal large b cell lymphoma,drug  sunitinib mal,phase 2
602,therapy patients untreated age adjusted international prognostic index low intermediate risk  high intermediate risk  high risk diffuse large b cell lymphoma,drug  etoposide  carboplatin  ifosfamide drug  rituximab  ifosfamide  etoposide  carboplatin drug  rituximab  ifosfamide  etoposide  carboplatin  stem cell collection  mitoxantrone  cyclophosphamide etoposide  carmustin,phase 2
603,trial vorinostat combination cyclophosphamide  etoposide  prednisone rituximab elderly patients relapsed diffuse large b cell lymphoma  dlbcl ,drug  rituximab  cyclophosphamide  etoposide  prednisone  vorinostat qol questionnaire  peg filgrastim filgrastim,phase 1 phase 2
604,genetically engineered lymphocytes  cyclophosphamide  aldesleukin treating patients relapsed refractory mantle cell lymphoma indolent b cell non hodgkin lymphoma,biological  therapeutic autologous lymphocytes drug  cyclophosphamide biological  aldesleukin genetic  polymerase chain reaction genetic  gene rearrangement analysis procedure  lymph node biopsy biological  genetically engineered lymphocyte therapy procedure  bone marrow aspiration flow cytometry laboratory biomarker analysis enzyme linked immunosorbent assay,phase 1
605,ct 011 mab dlbcl patients following asct,drug  ct 011,phase 2
606,cd19 targeting 3rd generation car cells refractory b cell malignancy   phase iia trial ,biological  autologous 3rd generation cd19 targeting car cel,phase 1 phase 2
607,interleukin 2 following 4scar19 22 cells targeting refractory recurrent b cell malign,biological  4scar19 22 cells drug  interleukin 2,phase 1 phase 2
608,cd19 targeting  3rd generation car cells refractory b cells malign,biological  car cel,phase 2
609,study investigational drug  asp3026  patients advanced malignancies  solid tumors b cell lymphoma ,drug  asp3026,phase 1
610,car cells refractory b cell malign,biological  autologous cd19 targeting car cel,phase 1 phase 2
611,lenalidomide combined modified da epoch rituximab  epoch r2  primary effusion lymphoma kshv associated large cell lymphoma,drug  lenalidomide drug  rituximab drug  prednisone drug  etopside drug  doxorubicin drug  vincristine drug  cyclophosphamid,phase 1 phase 2
612,anti cd19 car therapy bridging hsct cd19  b cell malign,genetic  second generation car cells procedure  hematological stem cell transplant,phase 1 phase 2
613,anti cd19 car therapy combine hsct treat mrd  b cell malign,genetic  second generation car cells procedure  hematological stem cell transplant,phase 1
614,efficacy safety proof concept study daratumumab relapsed refractory mantle cell lymphoma  diffuse large b cell lymphoma  follicular lymphoma,drug  daratumumab,phase 2
615,study obinutuzumab  rituximab  polatuzumab vedotin  venetoclax relapsed refractory follicular lymphoma  fl  diffuse large b cell lymphoma  dlbcl ,drug  obinutuzumab drug  rituximab drug  polatuzumab vedotin drug  venetoclax,phase 1
616,bortezomib vorinostat treating patients recurrent mantle cell lymphoma recurrent refractory diffuse large b cell lymphoma,drug  bortezomib laboratory biomarker analysis drug  vorinostat,phase 2
617,cd19 chimeric antigen receptor  car  modified cell therapy treating patients b cell malign,genetic  second generation car cel,phase 1
618,treatment relapsed chemotherapy refractory chronic lymphocytic leukemia indolent b cell lymphoma using autologous cells genetically targeted b cell specific antigen cd19,biological  therapeutic autologous lymphocytes drug  cyclophosphamid,phase 1 phase 2
619,study idasanutlin combination obinutuzumab relapsed refractory  r r  follicular lymphoma  fl  combination rituximab r r diffuse large b cell lymphoma  dlbcl  particip,drug  idasanutlin drug  obinutuzumab drug  rituximab,phase 1 phase 2
620,detection characterization residual masses lymphoma,nan,nan
621,phase 2 clinical trial rituxan b glucan pgg relapsed indolent non hodgkin lymphoma,drug  imprime pgg drug  rituximab,phase 2
622,clinical study compare efficacy safety rituximab biosimilar hlx01 rituximab combination chop  previously untreated subjects cd20  dlbcl,drug  hlx01 drug  rituximab drug  chop,phase 3
623,lenalidomide rituximab treatment relapsed mantle cell lymphoma  mcl  diffuse large b cell lymphoma,drug  lenalidomide drug  rituximab,phase 1 phase 2
624,tlr9 agonist sd 101  anti ox40 antibody bms 986178  radiation therapy treating patients low grade b cell non hodgkin lymphoma,biological  anti ox40 antibody bms 986178 laboratory biomarker analysis radiation  radiation therapy drug  tlr9 agonist sd 101,phase 1
625,intratumoral poly iclc plus low dose local radiation low grade recurrent b cell lymphoma,drug  poly iclc,phase 1
626,salvage therapy idarubicin relapsing cns lymphoma,drug  idarubicin,phase 2
627,phase ii trial combined modality treatment primary central nervous system lymphoma,drug  high dose methotrexate drug  high dose cytarabine radiation  radiotherapi,phase 2
628,rituxan vs bexxar combined carmustine  etoposide  cytarabine melphalan  beam  autologous hematopoietic stem cell transplantation  bmt ctn 0401 ,drug  autologous transplantation using rituxan beam drug  autologous transplantation using bexxar beam,phase 3
629,prospective multicenter dose finding phase ii pilot trial evaluate efficacy safety lr chop21 elderly patients untreated diffuse large b cell lymphoma,drug  lr chop21,phase 2
630,early evaluation response large b cell non hodgkin’lymphoma chemotherapy pet ct,procedure  pet ct 20 days first cycle chemotherapi,applicable
631,study syb l 0501 combination rituximab treat relapsed refractory diffuse large b cell lymphoma,drug  syb l 0501 drug  rituximab,phase 2
632,brentuximab vedotin  bendamustine  rituximab patients relapsed refractory b cell non hodgkin lymphoma,drug  brentuximab drug  bendamustine drug  rituximab,phase 2
633,study investigate safety  pharmacokinetics  pharmacodynamics clinical activity gsk2816126 subjects relapsed refractory diffuse large b cell lymphoma  transformed follicular lymphoma  non hodgkin lymphomas  solid tumors multiple myeloma,drug  gsk2816126,phase 1
634,study standard dose rituximab  ifosfamide  carboplatin etoposid,drug  velcade  bortezomib   rituximab  ifosfamide  carboplatin  etoposid,phase 1
635,selinexor plus combination chemotherapy treating patients advanced b cell non hodgkin lymphoma,drug  selinexor,phase 1 phase 2
636,obinutuzumab  venetoclax  lenalidomide treating patients relapsed refractory b cell non hodgkin lymphoma,drug  lenalidomide biological  obinutuzumab drug  venetoclax,phase 1
637,bnhl 2015 children adolescents china,drug  prednisone vincristine  cyclophosphamide drug  cyclophosphamide  vincristine  cytarabine  doxorubincin  prednisone drug  ifosphamide  etoposide  methotrexate  vincristine  prednisone drug  cyclophosphamide  vindelsine  cytarabine  doxorubincin  prednisone drug  ifosphamide  etoposide  methotrexate  vindelsine  prednisone drug  rituximab,phase 2 phase 3
638,kappa cd28 lymphocytes  chronic lymphocytic leukemia  b cell lymphoma multiple myeloma  chark,biological  kappa cd28 cel,phase 1
639,patients relapsed refractory diffuse large b cell non hodgkin lymphoma,drug  ofatumumab,phase 2
640,cd19 specific cell infusion patients b lineage lymphoid malign,procedure  leukapheresis procedure  stem cell transplant procedure  cd19 specific cell infusion drug  il 2 drug  carmustine drug  etoposide drug  cytarabine drug  melphalan,phase 1
641,tisagenlecleucel adult patients aggressive b cell non hodgkin lymphoma,drug  tisagenlecleucel optional bridging lymphodepleting chemotherapy drug  platinum based immunochemotherapy followed responding patients high dose chemotherapy hsct,phase 3
642,rituximab autologous stem cell transplant relapsed b cell non hodgkin lymphoma,drug  rituximab 375 mg m2,phase 2
643,phase 2 poor risk dlbcl tli atg followed matched allogeneic ht consolidation autologous hct,procedure  autologous hematopoietic stem cell transplantation  auto hsct  procedure  allogeneic hematopoietic stem cell transplantation  allo hsct  procedure  total lymphoid irradiation  tli  drug  rituximab drug  carmustine drug  etoposide drug  filgrastim drug  anti thymocyte globulin  atg  drug  cyclosporine drug  mycophenolate mofetil  mmf  drug  cyclophosphamide drug  acetaminophen drug  diphenhydramine drug  hydrocortisone drug  methylprednisolon,phase 2
644,phase ii study evaluate safety cellular immunotherapy using autologous cells engineered express cd20 specific chimeric antigen receptor patients relapsed refractory b cell non hodgkin lymphoma,biological  chimeric antigen receptor cell therapy drug  cyclophosphamide drug  fludarabine laboratory biomarker analysis procedure  leukapheresi,phase 1 phase 2
645,trial determine efficacy safety jcar017 adult subjects aggressive b cell non hodgkin lymphoma,drug  jcar017,phase 2
646,study ibrutinib combination bendamustine rituximab patients relapsed refractory aggressive bcl,drug  bendamustine 90 mg m2 iv days 1 2  cycles 1 6,phase 2
647,cpi 613  bendamustine hydrochloride  rituximab treating patients relapsed refractory b cell non hodgkin lymphoma,drug  6 8 bis benzylthio octanoic acid drug  bendamustine hydrochloride biological  rituximab laboratory biomarker analysi,phase 1
648,mt2017 45  car cell therapy heme malign,drug  kymriah drug  yescarta drug  fludarabine drug  cyclophosphamid,phase 2
649,phase ii trial alemtuzumab  campath  dose adjusted epoch rituximab  da epoch r  relapsed refractory diffuse large b cell hodgkin lymphoma,biological  campath biological  rituximab drug  epoch,phase 2
650,copanlisib rituximab relapsed indolent b cell non hodgkin lymphoma  inhl ,drug  copanlisib  bay 80 6946  drug  placebo drug  rituximab,phase 3
651,phase ii study ibrutinib patients relapsed refractory marginal zone lymphoma,drug  ibrutinib,phase 2
652,study lenalidomide maintenance versus placebo responding elderly patients dlbcl treated r chop,drug  lenalidomide drug  placebo,phase 3
653,study safety efficacy pharmacokinetics ct 1530 patients relapsed refractory b cell non hodgkin lymphoma  chronic lymphocytic leukemia  waldenstrom macroglobulinemia,drug  ct 1530,phase 1 phase 2
654,lenalidomide ibrutinib treating patients relapsed refractory b cell non hodgkin lymphoma,drug  ibrutinib drug  lenalidomide pharmacological studi,phase 1
655,effectiveness circulating dna predicting relapse overall survival nhl pati,nan,nan
656,vaccine therapy without cryosurgery treating patients residual  relapsed  refractory b cell non hodgkin lymphoma,biological  dendritic cell vaccine therapy procedure  cryotherapy biological  pneumococcal polyvalent vaccine laboratory biomarker analysis immunoenzyme technique immunohistochemistry staining method biological  autologous dendritic cell tumor fusion vaccin,applicable
657,hujcar014 car cells treating adult patients relapsed refractory b cell non hodgkin lymphoma acute lymphoblastic leukemia,biological  autologous human anti cd19car 4 1bb cd3zeta egfrt expressing cd4  cd8  lymphocytes drug  cyclophosphamide drug  fludarabine laboratory biomarker analysis procedure  leukapheresis pharmacological studi,phase 1
658,da epoch r induction followed nivolumab consolidation newly diagnosed myc  bcl2 bcl6 rearranged hgbl,drug  da epoch r followed nivolumab,phase 2
659,fusion protein cytokine therapy rituximab treating patients b cell non hodgkin lymphoma,biological  di leu16 il2 immunocytokine biological  rituximab flow cytometry immunohistochemistry staining method pharmacological study laboratory biomarker analysis enzyme linked immunosorbent assay genetic  reverse transcriptase polymerase chain react,phase 1
660,study obinutuzumab chinese participants cd20  malignant disea,drug  obinutuzumab,phase 1
661,lenalidomide rituximab maintenance therapy treating patients b cell non hodgkin lymphoma,drug  lenalidomide biological  rituximab genetic  polymerase chain reaction genetic  nucleic acid sequencing genetic  polymorphism analysis flow cytometry laboratory biomarker analysi,phase 1
662,umbilical cord blood nk cells  rituximab  high dose chemotherapy  stem cell transplant treating participants recurrent refractory b cell non hodgkin lymphoma,procedure  autologous hematopoietic stem cell transplantation drug  carmustine biological  cord blood derived expanded allogeneic natural killer cells drug  cytarabine drug  etoposide biological  filgrastim drug  lenalidomide drug  melphalan biological  rituximab,phase 2
663,study evaluating chemotherapy combination inotuzumab ozogamicin subjects non hodgkin lymphoma,drug  inotuzumab ozogamicin rituximab  cyclophosphamide vincristine prednisone drug  inotuzumab ozogamicin rituximab gemcitabine cisplatinum dexamethason,phase 1
664,investigational immuno therapy study determine safety urelumab given combination nivolumab solid tumors b cell non hodgkin lymphoma,biological  urelumab biological  nivolumab,phase 1 phase 2
665,cd22 redirected autologous cells ,biological  cart22 cells transduced lentiviral vector express anti cd22 scfv tcrz 41bb,phase 1
666,zevalin plus bucye high dose therapy b cell non hodgkin lymphoma,drug  zevalin bucy,phase 2
667,treatment non hodgkin lymphoma 90y hll2 igg,drug  radiolabeled epratuzumab,phase 1 phase 2
668,clinical study cd19 targeted car patients cd19  lymphoma leukemia,biological  icar19 car cel,phase 1
669,feasibility safety study universal dual specificity cd19 cd20 cd22 car cell immunotherapy relapsed refractory leukemia lymphoma,biological  universal dual specificity cd19 cd20 cd22 car cel,phase 1 phase 2
670,study evaluating ucart019 patients relapsed refractory cd19  leukemia lymphoma,biological  ucart019,phase 1 phase 2
671,phase ii study combined modality treatment primary testicular non hodgkin lymphoma,drug  rituximab drug  chop drug  intrathecal methotrexate procedure  radiotherapi,phase 2
672,trial hu5f9 g4 combination rituximab relapsed refractory b cell non hodgkin lymphoma,drug  hu5f9 g4 drug  rituximab,phase 1 phase 2
673,study patients non hodgkin lymphoma,drug  enzastaurin,phase 2
674,safety study assess afm11 patients relapsed refractory cd19 positive b cell nhl,drug  afm11,phase 1
675,study car 20 19 cells patients relapsed refractory b cell malign,biological  car 20 19 ,phase 1
676,retrospective analysis relapsed refractory aggressive non hodgkin lymphoma treated z beam plus asct,nan,nan
677,study efficacy safety ublituximab patients relapsed refractory b cell non hodgkin lymphoma,drug  ublituximab,phase 1 phase 2
678,phase iia study cart19 cells patients chemotherapy resistant refractory cd19  leukemia lymphoma,biological  cart 19,phase 1
679,long term follow study patients receiving car 20 19 cel,long term follow patients received car 20 19 cel,nan
680,treatment refractory relapsed non hodgkin lymphoma tricar cd19,biological  tricar cd19,phase 1 phase 2
681,avastin plus rituximab patients b cell non hodgkin lymphoma,drug  avastin drug  rituximab,phase 2
682,veltuzumab milatuzumab treating patients relapsed refractory b cell non hodgkin lymphoma,biological  milatuzumab biological  veltuzumab procedure  correlative special studies procedure  quantitative b   nk cell subsets procedure  pharmacokinetics procedure  human anti human antibodies biological  veltuzumab milatuzumab,phase 1 phase 2
683,observational study b cell non hodgkin lymphomas  nhl  associated hepatitis c virus  hcv ,nan,nan
684,single agent ofatumumab vs  single agent rituximab indolent b cell non hodgkin lymphoma relapsed rituximab containing therapi,biological  ofatumumab biological  rituximab,phase 3
685,rituximab  fludarabine  cyclophosphamide  yttrium 90 ibritumomab tiuxetan treating patients relapsed b cell non hodgkin lymphoma,biological  rituximab drug  cyclophosphamide drug  fludarabine phosphate radiation  yttrium 90 ibritumomab tiuxetan,phase 1 phase 2
686,clinical trial buparlisib ibrutinib lymphoma,drug  buparlisib drug  ibrutinib,phase 1
687,multi center study ibrutinib combination medi4736 subjects relapsed refractory lymphoma,drug  ibrutinib drug  medi4736,phase 1 phase 2
688,study evaluating safety efficacy jwcar029 adult subjects relapsed refractory b cell non hodgkin lymphoma,biological  jwcar029,phase 1
689,study evaluating safety efficacy jwcar029 adult subjects relapsed refractory b cell non hodgkin lymphoma,biological  jwcar029,phase 1
690,open label phase lb study ro7082859 atezolizumab adult patients relapsed refractory b cell non hodgkin lymphoma,drug  ro7082859 drug  atezolizumab drug  obinutuzumab,applicable
691,safety efficacy study ibrutinib pediatric young adult participants relapsed refractory mature b cell non hodgkin lymphoma,drug  ibrutinib drug  rituximab drug  ifosfamide drug  carboplatin drug  etoposide drug  vincristine drug  idarubicin drug  dexamethason,phase 3
692,ribomustin second line therapy relapsed refractory indolent b cell non hodgkin lymphoma,ribomustin rituximab,nan
693,study compare efficacy safety jcar017 standard care adult subjects high risk  transplant eligible relapsed refractory aggressive b cell non hodgkin lymphoma,drug  standard care genetic  jcar017,phase 3
694,ctl019 specification map dlbcl pati,biological  ctl019,nan
695,iit cti bendamustine  rituximab  pixantrone relapsed refractory b cell non hodgkin lymphoma,drug  bendamustine   rituximab   pixantron,phase 1 phase 2
696,phase study intrathecal rituximab patients lymphomatous men,drug  intrathecal rituximab,phase 1
697,study escalating doses dcds0780a participants relapsed refractory b cell non hodgkin lymphoma,drug  dcds0780a drug  rituximab drug  obinutuzumab,phase 1
698,bortezomib gemcitabine treating patients relapsed b cell non hodgkin lymphoma,biological  rituximab drug  bortezomib drug  gemcitabine hydrochloride questionnaire administr,phase 1 phase 2
699,ibrutinib treating relapsed refractory b cell non hodgkin lymphoma patients hiv infect,drug  ibrutinib laboratory biomarker analysis pharmacological studi,phase 1
700,dose adjusted epoch r  treat mature b cell malign,drug  da epoch r dlbcl  ptld  pmbcl drug  methotrexate drug  etoposide drug  doxorubicin drug  vincristine drug  rituximab drug  cyclophosphamide drug  prednisone drug  g csf,early phase 1
701,observational study patients malignant lymphomas treated mabthera® sc everyday clinical pract,nan,nan
702,r ice high dose cyclophosphamide pet ct diffuse large b cell non hodgkin lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone drug  ifosfamide drug  carboplatin drug  etoposide drug  high dose cyclophosphamide procedure  pet scan,phase 2
703,safety efficacy entospletinib  ento  gs 9973   combined vincristine  vcr  adult participants relapsed refractory b cell non hodgkin lymphoma  nhl ,drug  ento drug  vcr,phase 1 phase 2
704,xlcart001 treatment relapsed refractory high risk b cell malignancy subject,biological  chimeric antigen receptor cel,phase 2
705,study rituximab hcvad alternating rituximab methotrexate cytarabine versus standard rituximab chop every 21 days patients newly diagnosed high risk aggressive b cell non hodgkin lymphomas patients 60 years old young,drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  dexamethasone drug  methotrexate drug  cytarabine drug  prednison,phase 2
706,dose escalation study ro7082859 single agent combination obinutuzumab  administered fixed  single pre treatment dose obinutuzumab participants relapsed refractory b cell non hodgkin lymphoma,drug  ro7082859 drug  obinutuzumab drug  tocilizumab,phase 1
707,study polatuzumab vedotin combination rituximab obinutuzumab  cyclophosphamide  doxorubicin  prednisone participants b cell non hodgkin lymphoma,drug  cyclophosphamide drug  doxorubicin drug  obinutuzumab drug  polatuzumab vedotin drug  prednisolone drug  prednisone drug  rituximab,phase 1 phase 2
708,phase 2 study zevalin versus zevalin motexafin gadolinium patients rituximab refractory low grade follicular b cell non hodgkin lymphoma,drug  zevalin regimen drug  moxtezafin gadolinium,phase 2
709,drug drug interaction study ofatumumab bendamustine subjects indolent b cell non hodgkin lymphoma,drug  ofatumumab drug  bendamustin,phase 1
710,ofatumumab bendamustine followed maintenance ofatumumab rituximab relapsed indolent b cell non hodgkin lymphoma  b nhl ,biological  ofatumumab drug  bendamustin,phase 2
711,phase trial di b4 patients advanced cd19 positive indolent b cell malign,drug  di b4,phase 1
712,safety ibritumomab tiuxetan  zevalin®  combination fludarabine based reduced intensity conditioning  ric  regimen  zevallo 2007 ,drug  ibritumomab tiuxetan  zevalin ,phase 2
713,chimeric antigen receptor cells  cart  therapy refractory relapsed b cell hematologic malign,biological  cd19cart,applicable
714,high dose therapy autologous stem cell transplantation followed infusion chimeric antigen receptor  car  modified cells directed cd19  b cells relapsed refractory aggressive b cell non hodgkin lymphoma,drug  carmustine drug  etoposide drug  cytarabine drug  melphalan biological  pegfilgrastim biological  19 28z cells procedure  autologous stem cell transplant,phase 1
715,rituximab denileukin diftitox treating patients previously untreated stage iii stage iv follicular b cell non hodgkin lymphoma,biological  denileukin diftitox biological  rituximab,phase 2
716,communication skills intervention promote transition survivorship,nan,nan
717,90 ibritumomab tiuxetan  rituximab relapsed refractory diffuse large b cell non hodgkin lymphoma,biological  rituximab drug  cytarabine drug  liposomal cytarabine radiation  yttrium 90 ibritumomab tiuxetan,phase 2
718,combination chemotherapy rituximab treating patients newly diagnosed aids related b cell non hodgkin lymphoma,biological  filgrastim biological  pegfilgrastim biological  rituximab biological  sargramostim drug  cyclophosphamide drug  pegylated liposomal doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate immunohistochemistry staining method laboratory biomarker analysi,phase 2
719,study evaluate efficacy safety treatment bendamustine combination ofatumumab previously untreated patients indolent b cell non hodgkin lymphoma  nhl ,drug  bendamustine hydrochloride drug  ofatumumab,phase 2
720,prospective comparison fdg pet mr fdg pet ct classical hodgkin lymphoma dlbc non hodgkin lymphoma,nan,nan
721,safety tolerability study sns01 relapsed refractory b cell malignancies  multiple myeloma  b cell lymphoma  plasma cell leukemia  pcl ,biological  sns01 ,phase 1 phase 2
722,pxd101 treating patients relapsed refractory aggressive b cell non hodgkin lymphoma,drug  belinostat,phase 2
723,multi dose escalation safety pharmacokinetic study sar3419 single agent relapsed refractory b cell non hodgkin lymphoma,drug  sar3419,phase 1
724,observation patients diffuse large b cell non hodgkin lymphoma treated clinical trial ncic ly9,clinical observation procedure  management therapy compl,nan
725,rituximab  cyclophosphamide  vincristine sulfate  prednisone without liposome encapsulated doxorubicin citrate treating older patients stage ii  stage iii  stage iv diffuse large b cell non hodgkin lymphoma,biological  filgrastim biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  liposome encapsulated doxorubicin citrate drug  prednisone drug  vincristine sulf,phase 2
726,combination chemotherapy rituximab pegfilgrastim followed rituximab  large b cell non hodgkin lymphoma,drug  cyclophosphamide drug  mitoxantrone drug  vincristine drug  prednisone drug  rituximab,phase 2
727,study sgn 40 combination rituximab patients cd20 positive  follicular marginal zone b cell non hodgkin lymphoma,drug  rituximab drug  sgn 40,phase 1
728,antiviral agent harvoni® treatment hcv associated indolent b cell lymphoma,drug  ledipasvir sofosbuvir,phase 2
729,decrease fatigue light therapi,device  light therapy intensity 1 device  light therapy intensity 2,phase 3
730,comprehensive geriatric assessment predict toxic events older patients non hodgkin lymphoma imbedded pilot study pre phase therapi,drug  rituximab drug  prednisone behavioral  geriatric assess,applicable
731,study acalabrutinib alone combination rituximab indolent b cell non hodgkin lymphoma,drug  acalabrutinib drug  rituximab  iv ,phase 1 phase 2
732,phase 1 study sb1518 treatment advanced lymphoid malign,drug  sb1518,phase 1
733,maintenance rituximab mtor inhibition high dose consolidative therapy lymphoma,drug  everolimus rituximab,phase 2
734,active specific immunotherapy follicular lymphomas tumor derived immunoglobulin idiotype antigen vaccin,drug  id klh vaccine drug  gm csf,phase 1
735,yttrium 90 ibritumomab tiuxetan  rituximab  indium 111 ibritumomab tiuxetan  fludarabine  melphalan  donor stem cell transplant treating patients b cell non hodgkin lymphoma,biological  rituximab drug  fludarabine phosphate drug  melphalan drug  sirolimus drug  tacrolimus procedure  allogeneic hematopoietic stem cell transplantation radiation  indium 111 ibritumomab tiuxetan radiation  yttrium 90 ibritumomab tiuxetan laboratory biomarker analysi,phase 2
736,study 5 azacitidine combination vorinostat patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  azacytidine drug  vorinostat,phase 1 phase 2
737,clinical study syb l 0501 patients indolent b cell non hodgkin lymphoma mantle cell lymphoma,drug  bendamustine hydrochlorid,phase 2
738,azd6738 first time patient multiple ascending dose studi,drug  administration azd6738,phase 1
739,memory enriched cells following stem cell transplant treating patients recurrent b cell non hodgkin lymphoma,biological  autologous cd19car cd28 cd3zeta egfrt expressing tcm enriched cells biological  autologous cd19car cd28 cd3zeta egfrt expressing tn mem enriched lymphocytes laboratory biomarker analysi,phase 1
740,rituximab combination chemotherapy treating older patients diffuse large b cell lymphoma,biological  filgrastim biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  pegylated liposomal doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 2
741,ofatumumab bendamustine combination therapy compared bendamustine monotherapy indolent b cell non hodgkin lymphoma  nhl  unresponsive rituximab rituximab containing regimen,drug  ofatumumab bendamustine infusions  arm drug  bendamustine infusion  arm b ,phase 3
742,rituximab combination chemotherapy without radiation therapy treating patients b cell non hodgkin lymphoma,biological  filgrastim biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate radiation  radiation therapi,phase 3
743,epirubicin rituximab treating patients relapsed refractory b cell non hodgkin lymphoma chronic lymphocytic leukemia,biological  rituximab drug  epirubicin hydrochlorid,phase 2
744,combination chemotherapy rituximab treating patients diffuse large b cell non hodgkin lymphoma,biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  cytarabine drug  doxorubicin hydrochloride drug  etoposide phosphate drug  ifosfamide drug  leucovorin calcium drug  methotrexate drug  vincristine sulf,phase 2
745,vaccination follicular lymphomas tumor derived immunoglobulin idiotyp,drug  id klh vaccine drug  qs 21  stimulation qs 21  drug,phase 1
746,cd19 cd22 chimeric antigen receptor cells chemotherapy treating patients recurrent refractory cd19 positive diffuse large b cell lymphoma b acute lymphoblastic leukemia,biological  chimeric antigen receptor cell therapy drug  cyclophosphamide drug  fludarabine phosphate laboratory biomarker analysis questionnaire administr,phase 1
747,yttrium 90 ibritumomab tiuxetan plus high dose beam followed asct relapsed b cell non hodgkin lymphoma,biological  rituximab drug  carmustine drug  cytarabine drug  etoposide drug  melphalan procedure  asct radiation  yttrium 90 ibritumomab tiuxetan,phase 2
748,study blinatumomab patients pre b cell b cell nhl post allo hsct remission mainten,drug  blinatumomab drug  dexamethason,early phase 1
749,lenalidomide without rituximab standard chemotherapy treating patients diffuse large b cell non hodgkin lymphoma,drug  lenalidomide drug  rituximab,phase 2
750,pivotal study iodine 131 tositumomab chemotherapy refractory low grade transformed low grade b cell non hodgkin lymphoma,biological  tositumomab iodine 131 tositumomab,phase 2
751,rituximab treating patients undergoing donor peripheral blood stem cell transplant relapsed refractory b cell lymphoma,biological  rituximab procedure  peripheral blood stem cell transplantation procedure  nonmyeloablative allogeneic hematopoietic stem cell transplantation pharmacological study laboratory biomarker analysi,phase 2
752,ibrutinib  rituximab  etoposide  prednisone  vincristine sulfate  cyclophosphamide  doxorubicin hydrochloride treating patients hiv positive stage ii iv diffuse large b cell lymphoma,drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide biological  filgrastim drug  ibrutinib laboratory biomarker analysis biological  pegfilgrastim pharmacological study drug  prednisone biological  rituximab drug  vincristine sulf,phase 1
753,fr901228 alone combined rituximab fludarabine treating patients relapsed refractory low grade b cell non hodgkin lymphoma,drug  romidepsin biological  rituximab drug  fludarabine phosphate laboratory biomarker analysi,phase 2
754,study two associations rituximab chemotherapy  pet driven strategy  lymphoma,drug  r chop14 induction regimen drug  r acvbp14 induction regimen,phase 2
755,safety efficacy study dual pi3k delta gamma inhibitor hematological malign,drug  rp6530,phase 1
756,study vorinostat  mk0683  follicular lymphoma  fl   indolent b cell non hodgkin lymphoma  b nhl  mantle cell lymphoma  mcl  patients  mk 0683 103 ,drug  vorinostat,phase 2
757,onalespib treating patients relapsed refractory anaplastic large cell lymphoma  mantle cell lymphoma  diffuse large b cell lymphoma,laboratory biomarker analysis drug  onalespib,phase 2
758,efficacy safety study idelalisib subjects indolent b cell non hodgkin lymphoma,drug  idelalisib,phase 2
759,study mdx 1203 subjects advanced recurrent clear cell renal cell carcinoma  ccrcc  relapsed refractory b cell non hodgkin lymphoma  b nhl ,biological  mdx 1203,phase 1
760,study bruton tyrosine kinase inhibitor combination rituximab previously untreated subjects follicular lymphoma,drug  ibrutinib drug  rituximab,phase 2
761,phase ii study intratumoral injection sd 101,biological  ipilimumab drug  sd 101 radiation  radiation therapi,phase 1 phase 2
762,pembrolizumab alone idelalisib ibrutinib treating patients relapsed refractory chronic lymphocytic leukemia low grade b cell non hodgkin lymphoma,drug  ibrutinib drug  idelalisib laboratory biomarker analysis biological  pembrolizumab,phase 2
763,proclaim cx 2029  trial find safe active doses investigational drug cx 2029 patients solid tumors dlbcl,drug  cx 2029,phase 1 phase 2
764,safety study cat 8015 treat advanced b cell non hodgkin lymphoma chronic lymphocytic leukemia  nhl cll ,drug  cat 8015 20 mcg kg drug  cat 8015 30 mcg kg drug  cat 8015 40 mcg kg drug  cat 8015 50 mcg kg drug  cat 8015 60 mcg kg,phase 1 phase 2
765,safety  tolerability  pharmacokinetics idelalisib japanese adults relapsed refractory indolent b cell non hodgkin lymphomas chronic lymphocytic leukemia,drug  idelalisib,phase 1
766,pembro   blina combination pediatric young adult patients relapsed refractory acute leukemia lymphoma,drug  blinatumomab drug  pembrolizumab,phase 1
767,velcade rituximab cyclophosphamide decadron,drug  velcade® drug  rituximab drug  cyclophosphamide drug  decadron,phase 2
768,bryostatin 1 rituximab treating patients b cell non hodgkin lymphoma chronic lymphocytic leukemia,biological  rituximab drug  bryostatin 1,phase 2
769,cells expressing fully human anticd19 chimeric antigen receptor treating b cell malign,biological  anti cd19 car cells drug  cyclophosphamide drug  fludarabin,phase 1
770,assessment cellular proliferation tumors positron emission tomography  pet  using  18f iso 1,radiation  pet ct laboratory testing safety testing immunohistochemistry staining drug  f 18 iso,phase 1
771,factors influencing hepatitis b virus reactivation lymphoma patients treated rituximab,nan,nan
772,mgcd0103 administered combination azacitidine  vidaza®  subjects relapsed refractory hodgkin non hodgkin lymphoma,drug  mgcd0103 azacitidin,phase 2
773,velcade malt lymphoma pretreated prior systemic therapi,drug  bortezomib  drug ,phase 2
774,study safety pharmacokinetics escalating doses dcdt2980s patients relapsed refractory b cell non hodgkin lymphoma chronic lymphocytic leukemia dcdt2980s combination rituximab patients relapsed refractory b cell non hodgkin lymphoma,drug  dcdt2980s drug  rituximab,phase 1
775,study escalating doses polatuzumab vedotin participants relapsed refractory b cell non hodgkins lymphoma chronic lymphocytic leukemia polatuzumab vedotin combination rituximab participants relapsed refractory b cell non hodgkins lymphoma,drug  polatuzumab vedotin drug  rituximab,phase 1
776,velcade malt lymphoma pretreated one prior systemic therapi,drug  bortezomib  drug ,phase 2
777,randomized trial chlorambucil versus chlorambucil plus rituximab versus rituximab malt lymphoma,drug  chlorambucil  drug  drug  rituximab chlorambucil drug  rituximab,phase 3
778,phase 1 2 study vsli plus rituximab patients relapsed refractory nhl,drug  vincristine sulfate liposome injection plus rituximab,phase 1 phase 2
779,safety efficacy study cnto 328 patients b cell non hodgkin lymphoma  multiple myeloma  castleman disea,drug  cnto 328,phase 1
780,vincristine sulfate liposome injection  marqibo®   bendamustine rituximab—phase trial indolent b cell lymphoma,drug  rituximab drug  bendamustine drug  vincristine sulfate liposome inject,phase 1
781,bortezomib flavopiridol treating patients recurrent refractory indolent b cell neoplasm,drug  bortezomib drug  alvocidib hydrochloride pharmacological studi,phase 1
782,study investigate idelalisib combination chemotherapeutic agents  immunomodulatory agents anti cd20 monoclonal antibody  mab  subjects relapsed refractory indolent b cell non hodgkin lymphoma  mantle cell lymphoma chronic lymphocytic leukemia,drug  idelalisib drug  rituximab drug  bendamustine drug  ofatumumab drug  fludarabine drug  everolimus drug  bortezomib drug  chlorambucil drug  lenalidomid,phase 1
783,blood immunophenotyping staging indolent b cell lymphomas v1 0,nan,nan
784,role cx3cr1 expressing cells hematologic malign,nan,nan
785,study 401 subjects cll sll  fl  b cell non hodgkin lymphoma,drug  401 drug  rituximab,phase 1
786,rituxan bendamustine pci 32765 relapsed dlbcl  mcl  indolent non hodgkin lymphoma,drug  btk inhibitor pci 32765 biological  rituximab drug  bendamustine hydrochloride pharmacogenomic studies pharmacological study laboratory biomarker analysi,phase 1
787,s8516 s8736 s9125 s9240 research study genes tissue samples patients b cell non hodgkin lymphoma,genetic  polymorphism analysis laboratory biomarker analysis pharmacogenomic studi,nan
788,depocyt active lymphomatous leukemic men,drug  cytarabine liposome inject,phase 2
789,obinutuzumab treating patients central nervous system lymphoma achieved complete respon,procedure  cognitive assessment biological  obinutuzumab quality life assess,phase 2
790,phase trial azd3965 patients advanced canc,drug  azd3965,phase 1
791,thalidomide maintenance treatment dlbcl,drug  thalidomide observ,phase 3
792,cd19 targeting car cells relapsed refractory cd19 positive b cell malign,biological  cd19 car ,phase 1
793,value mechanisms monocytes subpopulations predicting prognosis lymphoma,nan,nan
794,gemcitabine marginal zone lymphoma,drug  gemcitabin,phase 2
795,cells expressing anti cd19 car pediatric young adults b cell malign,biological  cd19 car cel,phase 1 phase 2
796,safety study sgn cd19a b cell lymphoma,drug  sgn cd19a,phase 1
797,cd34  selected asct aggressive lymphoma,procedure  cd34  cell select,phase 2
798,study evaluate efficacy tolerance r gemox dlbcl mcl,drug  rituximab  gemcitabine  oxaliplatin  dexametason,phase 2
799,oblimersen sodium rituximab treating patients recurrent b cell non hodgkin lymphoma,biological  oblimersen sodium biological  rituximab laboratory biomarker analysi,phase 2
800,cmv induced changes nk lymphocyte biology influence effectiveness antibody therapy used treat b cell lymphoproliferative diseases ,nan,nan
801,first time humans  ftih  study gsk3368715 subjects solid tumors diffuse large b cell lymphoma  dlbcl ,drug  gsk3368715,phase 1
802,multiple ascending dose study medi7247 patients selected relapsed refractory hematological malign,drug  medi7247,phase 1
803,p53 p16 independent epigenetic therapy oral decitabine tetrahydrouridine refractory relapsed lymphoid malign,drug  decitabine drug  tetrahydrouridin,early phase 1
804,yttrium 90 ibritumomab tiuxetan  fludarabine  radiation therapy  donor stem cell transplant treating patients relapsed refractory non hodgkin lymphoma,biological  rituximab drug  cyclosporine drug  fludarabine phosphate drug  mycophenolate mofetil radiation  yttrium 90 ibritumomab tiuxetan procedure  peripheral blood stem cell transplantation procedure  allogeneic hematopoietic stem cell transplantation radiation  total body irradi,phase 2
805,combination pentostatin  bendamustine ofatumumab treatment chronic lymphocytic leukemia lymphoma,drug  bendamustine drug  pentostatin drug  ofatumumab,phase 1
806,safety efficacy study dual specificity cd19 cd22 car cell immunotherapy relapsed refractory lymphoma,drug  dual specificity cd19 cd22 car cell immunotherapi,phase 1
807,1630gcc  zydelig maintenance b cell non hodgkin lymphoma autologous stem cell transpl,drug  zydelig,phase 2
808,rituximab interleukin 12 treating patients b cell non hodgkin lymphoma,biological  rituximab biological  recombinant interleukin 12 laboratory biomarker analysis questionnaire administration procedure  quality life assess,phase 2
809,cd19 targeted car cell therapy mrd  b cell malignancies autologous stem cell transpl,biological  cd19 targeted car cel,applicable
810,phase ii study chlorambucil subcutaneous rituximab patients extranodal malt lymphoma,drug  chlorambucil drug  rituximab v  drug  rituximab c ,phase 2
811,ofatumumab bortezomib patients low grade b cell non hodgkin lymphoma relapse rituximab,drug  ofatumumab bortezomib,phase 2
812,mdx 010 treating patients recurrent refractory lymphoma,biological  ipilimumab laboratory biomarker analysi,phase 1 phase 2
813,phase ii study ontak previously treated patients low grade non hodgkin lymphoma  nhl ,drug  ontak,phase 2
814,phase ii study pembrolizumab patients failing respond relapsing anti cd19 chimeric antigen receptor modified cell therapy relapsed refractory cd19  lymphoma,drug  pembrolizumab,phase 1 phase 2
815,phase ii study ofatumumab plus ifosfamide  carboplatin  etoposide  ice  dexamethasone  cytarabine  cisplatin  dhap  chemotherapy regimen relapsed  refractory diffuse large b cell lymphoma  dlbcl ,drug  ofatumumab   ice drug  ofatumumab   dhap,phase 2
816,phase ii open label trial determine safety   efficacy tisagenlecleucel pediatric non hodgkin lymphoma pati,biological  tisagenlecleucel,phase 2
817,pnt2258 treatment patients r r dlbcl  wolverine ,drug  pnt2258,phase 2
818,durvalumab dlbcl autologous transpl,drug  durvalumab,phase 2
819,goal  ga101 plus pixantrone relapsed aggressive lymphoma,drug  obinutuzumab pixantron,phase 2
820,memory enriched car cells immunotherapy b cell lymphoma,drug  cd19 car cel,phase 1 phase 2
821,iodine 131 tositumomab fludarabine phosphate treating older patients undergoing autologous syngeneic stem cell transplant relapsed refractory non hodgkin lymphoma,drug  fludarabine phosphate procedure  peripheral blood stem cell transplantation radiation  iodine 131 tositumomab laboratory biomarker analysis flow cytometry genetic  polymerase chain react,phase 1
822,clinical study evaluating safety efficacy bind19 treatment r r lymphoma subject,biological  bind19,phase 1 phase 2
823,combination obinutuzumab venetoclax relapsed refractory dlbcl,drug  venetoclax drug  obinutuzumab,phase 2
824,ruxolitinib phosphate treating patients relapsed refractory diffuse large b cell peripheral cell non hodgkin lymphoma donor stem cell transpl,laboratory biomarker analysis drug  ruxolitinib phosph,phase 2
825,mb cart20 1 lymphoma,biological  mb cart20 1,phase 1 phase 2
826,investigation human immune response normal subjects patients disorders immune system canc,nan,nan
827,phase 1b open label study evaluate safety efficacy cc 122 obinutuzumab  ga101  relapsed refractory dlbcl inhl ,drug  obinutuzumab drug  cc 122,phase 1
828,clinical study evaluating safety efficacy bind19 treatment childhood r r lymphoma subject,biological  bind19,phase 1 phase 2
829,emd 521873 advanced solid tumors  mtd find,biological  emd 521873,phase 1
830,combination chemo  rituximab  bevacizumab older patients stage ii iv diffuse large b cell lymphoma,biological  rituximab biological  bevacizumab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone laboratory biomarker analysi,phase 2
831,bendamustine hydrochloride  rituximab  etoposide  carboplatin treating patients relapsed refractory diffuse large b cell lymphoma hodgkin lymphoma,drug  bendamustine hydrochloride drug  carboplatin biological  rituximab drug  etoposide laboratory biomarker analysi,phase 1 phase 2
832,comparison study doxorubicin versus epirubicin induced cardiotoxicity patients dlbcl,drug  ceop regimen drug  chop regimen,phase 3
833,study evaluate safety tolerability xmab13676 patients cd20 expressing hematologic malign,biological  xmab13676,phase 1
834,dendritic cell vaccine treating patients indolent b cell lymphoma multiple myeloma,biological  autologous lymphoma cell lysate pulsed autologous dendritic cell vaccine biological  autologous lymphoma cell allogeneic dendritic cell electrofusion hybrid vaccine biological  autologous lymphoma cell autologous dendritic cell electrofusion hybrid vaccin,phase 1 phase 2
835,study evaluate safety efficacy combination mk 4280 pembrolizumab  mk 3475  participants hematologic malignancies  mk 4280 003 ,biological  pembrolizumab biological  mk 4280,phase 1 phase 2
836,r acvbp da epoch r patients non gcb dlbcl,drug  rituximab drug  etoposide drug  doxorubicin drug  vincristine drug  cyclophosphamide drug  prednisone drug  vindesine drug  bleomycin,phase 3
837,alisertib combination vorinostat treating patients relapsed recurrent hodgkin lymphoma  b cell non hodgkin lymphoma  peripheral cell lymphoma,drug  alisertib laboratory biomarker analysis pharmacological study drug  vorinostat,phase 1
838,bms pd l1 onco   assessment pd l1 protein biomarker oncology hematolog,nan,nan
839,immunotherapy bispecific car cells b cell lymphoma  cl,biological  anti cd19 anti cd20 bispecific car ,phase 1
840,immunotherapy cd19 car cells b cell lymphoma  cl,biological  anti cd19 car,phase 1
841,biomarker driven intensified chemoimmunotherapy early cns prophylaxi,combination product  r choep combination product  da epoch r,phase 2
842,immunotherapy cd19 car γδt cells b cell lymphoma  cl,biological  anti cd19 car γδt,phase 1
843,alisertib  bortezomib  rituximab treating patients relapsed refractory mantle cell lymphoma b cell low grade non hodgkin lymphoma,drug  alisertib drug  bortezomib laboratory biomarker analysis biological  rituximab,phase 1
844,prospective data collection elderly patients dlbcl receiving time diagnosis vgm,nan,nan
845,phase ii study ga101 dhap induction therapy relapsed refractory dlbcl pati,drug  ga101 dhap,phase 2
846,cart 19 immunotherapy mantle cell lymphoma,biological  anti cd19 car vector transduced cel,phase 1 phase 2
847,cart19 cells treatment mrd b cell malignancies auto hsct,biological  cart19 cell auto hsct,phase 1
848,anti cd19 white blood cells children young adults b cell leukemia lymphoma,biological  anti cd19  car,phase 1
849,autologous transplant hiv patients  bmt ctn 0803 ,procedure  autologous transplant drug  bcnu drug  etoposide drug  cytarabine drug  melphalan,phase 2
850,rituximab bendamustine elderly patients elderly medically non fit patients aggressive b cell lymphoma,drug  bendamustine subcutaneous rituximab,phase 2
851,determine dose bi 836826 gemox efficacy bi 836826 gemox versus r gemox patients relapsed refractory dlbcl,drug  bi 836826 drug  gemox drug  rituximab,phase 2
852,trial define safety tolerability sgn 40  rituximab  gemcitabine patients dlbcl,drug  sgn 40 drug  rituximab drug  gemcitabin,phase 1
853,evaluation atezolizumab venetoclax obinutuzumab combination relapse refractory lymphoma,drug  atezolizumab drug  obinutuzumab drug  venetoclax,phase 2
854,ofatumumab bortezomib subjects relapsed cd20 diffuse large b cell  follicular  mantle cell lymphoma,biological  ofatumumab drug  bortezomib,phase 2
855,randomized phase iib placebo controlled study r ice chemotherapy without sgn 40 patients dlbcl,drug  sgn 40 drug  placebo drug  rituximab drug  etoposide drug  carboplatin drug  ifosfamid,phase 2
856,platform study treatment relapsed refractory aggressive non hodgkin lymphoma  prism study ,drug  azd9150 drug  acalabrutinib drug  azd6738,phase 1
857,rituximab plus interleukin 2 treating patients lymphoma,biological  aldesleukin biological  rituximab,phase 1 phase 2
858,dose adjusted epoch chemotherapy rituximab  cd20   previously untreated aggressive non hodgkin lymphoma,drug  epoch biological  rituximab,phase 2
859,zevalin beam rituximab vs beam rituximab without rituximab autologous stem cell transpl,drug  zevalin drug  carmustine drug  etoposide drug  cytarabine drug  melphalan drug  rituximab procedure  stem cell transpl,phase 2
860,chemotherapy patients lymphoma,drug  enzastaurin drug  gemcitabine drug  rituximab drug  oxaliplatin,phase 2
861,rituximab  cyclophosphamide  g csf followed combination chemotherapy treating patients undergoing autologous stem cell transplant followed rituximab gm csf refractory diffuse large b cell lymphoma,biological  filgrastim biological  rituximab biological  sargramostim drug  carmustine drug  cyclophosphamide drug  etoposide procedure  adjuvant therapy procedure  bone marrow ablation stem cell support procedure  peripheral blood stem cell transplant,phase 2
862,rituximab combined eshap patients relapse refractory diffuse large b cell lymphoma  dlbcl ,drug  rituximab combined eshap,phase 2
863,bortezomib rituximab treating patients non hodgkin lymphoma,drug  bortezomib   rituximab,phase 2
864,study trifunctional antibody fbta05 donor lymphocyte infusion b cell lymphoma allogeneic stem cell transpl,drug  fbta05,phase 1 phase 2
865,combination chemotherapy  rituximab  yttrium 90 ibritumomab tiuxetan treating patients newly diagnosed large b cell lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate radiation  yttrium 90 ibritumomab tiuxetan,phase 2
866,beta alethine treating patients low grade lymphoma,drug  beta alethin,phase 1 phase 2
867,bortezomib romidepsin patients chronic lymphocytic leukemia small lymphocytic lymphoma,drug  bortezomib drug  romidepsin,phase 1
868,safety  tolerability  pharmacokinetics shc014748m patients indolent b cell hematologic malign,drug  shc014748m,phase 1
869,rituximab liposomal doxorubicin treating patients relapsed refractory non hodgkin lymphoma,biological  rituximab drug  pegylated liposomal doxorubicin hydrochlorid,phase 1 phase 2
870,retrospective review gemcitabine  methylprednisolone cisplatin  gem p  without rituximab patients relapsed refractory diffuse large b cell lymphoma  dlbcl ,drug  gemcitabine drug  cisplatinum drug  rituximab,nan
871,ixazomib citrate rituximab treating patients indolent b cell non hodgkin lymphoma,drug  ixazomib citrate laboratory biomarker analysis biological  rituximab,phase 2
872,study comparing zevalin regimen treatment dlbcl patients complete remission chop r,drug  zevalin therapeutic regimen observ,phase 3
873,rituximab combination chemotherapy treating patients non hodgkin lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 3
874,phase ii study viper  chemotherapy rel ref dlbcl,drug  bortezomib  dexamethasone  ifosfamide drug  mesna  cisplatin  etoposide  rituximab,phase 2
875,brentuximab vedotin cd30 positive epstein barr virus  ebv  positive dlbcl elderli,drug  brentuximab vedotin,applicable
876,study veltuzumab 90y epratuzumab relapsed refractory  aggressive nhl,drug  veltuzumab 90y epratuzumab tetraxetan drug  90y epratuzumab tetraxetan drug  veltuzumab,phase 1 phase 2
877,revlimid dose 25 mg association r chop  treatment follicular lymphoma,drug  lenalidomide r chop,phase 2
878,study carfilzomib vorinostat relapsed refractory lymphoma,drug  drug  carfilzomib drug  vorinostat,phase 1
879,ph ii chop velcade mediastinal lbcl,drug  bortezomib drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednisone radiation  radiation therapi,phase 2
880,assessment minimal residual disease dlbcl cell free circulating dna ng,next generation sequencing device  fluorine 18 fluorodeoxyglucose positron emission tomography  18f fdg pet ,applicable
881,study brentuximab vedotin relapsed refractory non hodgkin lymphoma,drug  brentuximab vedotin drug  rituximab,phase 2
882,nivolumab gemcitabine  oxaliplatin   rituximab r r elderly lymphoma pati,drug  nivolumab drug  rituximab drug  gemcitabine device  oxaliplatin,phase 2 phase 3
883,incidence hepatitis b virus  hbv  reactivation hbsag negative hbcab positive lymphoma patients treated rchop,drug  nucleoside analog reverse transcriptase inhibitor,phase 2 phase 3
884,lisocabtagene maraleucel  jcar017  second line therapy  transcend nhl 006 ,biological  lisocabtagene maraleucel,phase 2
885,radiolabeled monoclonal antibody treating patients previously treated large cell lymphoma,radiation  iodine 131 monoclonal antibody lym 1,phase 1
886,monoclonal antibody therapy treating patients recurrent refractory lymphoma,biological  monoclonal antibody mono dga rfb4,phase 1
887,rituximab  vaccine therapy  gm csf treating patients non hodgkin lymphoma,biological  autologous immunoglobulin idiotype klh conjugate vaccine biological  rituximab biological  sargramostim,phase 2
888,genes predicting outcome patients dlbcl treated rituximab combination chemotherapy  r chop ,drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  prednisone drug  vincristin,phase 2
889,study investigational sar245409 patients certain lymphoma leukemia,drug  sar245409,phase 2
890,feasibility clinical efficacy atezolizumab consolidation treatment high risk  ipi   2  dlbcl,drug  atezolizumab,phase 2
891,mabrella study  study evaluate safety switching intravenous subcutaneous administration rituximab first line treatment lymphoma,drug  rituximab,phase 3
892,title less intensive therapy children non hodgkin lymphoma,biological  filgrastim drug  cyclophosphamide drug  cytarabine drug  doxorubicin hydrochloride drug  etoposide drug  methotrexate drug  prednisolone drug  prednisone drug  therapeutic hydrocortisone drug  vincristine sulf,phase 3
893,chemotherapy rituximab without total body irradiation peripheral stem cell transplant treating patients lymphoma,biological  filgrastim biological  rituximab drug  carboplatin drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide drug  ifosfamide drug  prednisone drug  vincristine sulfate procedure  peripheral blood stem cell transplantation radiation  radiation therapi,phase 2
894,photodynamic therapy treating patients lymphoma chronic lymphocytic leukemia,drug  aminolevulinic acid hydrochlorid,phase 2
895,study patients lymphoma take r chop enzastaurin compared patients take r chop ,drug  enzastaurin drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 2
896,rituximab addition autologous transplantation beam patients lymphoid malign,drug  carmustine drug  etoposide drug  cytarabine drug  melphalan drug  rituximab,phase 2
897,chemotherapy  radiation therapy  rituximab  umbilical cord blood transplant treating patients b cell non hodgkin lymphoma,biological  filgrastim biological  rituximab drug  cyclophosphamide drug  cyclosporine drug  fludarabine phosphate drug  mycophenolate mofetil procedure  allogeneic hematopoietic stem cell transplantation procedure  umbilical cord blood transplantation radiation  total body irradi,phase 2
898,vaccine therapy plus sargramostim following chemotherapy treating patients stage iii stage iv non hodgkin lymphoma,biological  keyhole limpet hemocyanin biological  sargramostim biological  tumor cell based vaccine therapi,phase 2
899,eltrombopag bcl extra large  xl  pathway idiopathic thrombocytopenic purpura  itp ,drug  promacta  eltrombopag ,phase 2
900,chemotherapy  total body irradiation  rituximab  donor stem cell transplant treating patients b cell non hodgkin lymphoma chronic lymphocytic leukemia,biological  anti thymocyte globulin biological  filgrastim biological  graft versus tumor induction therapy biological  rituximab drug  cyclophosphamide drug  cyclosporine drug  fludarabine phosphate drug  mycophenolate mofetil procedure  nonmyeloablative allogeneic hematopoietic stem cell transplantation radiation  total body irradi,phase 2
901,vaccine therapy plus sargramostim following chemotherapy treating patients previously untreated aggressive non hodgkin lymphoma,biological  keyhole limpet hemocyanin biological  sargramostim biological  tumor cell based vaccine therapy drug  cyclophosphamide drug  doxorubicin hydrochloride drug  mitoxantrone hydrochloride drug  prednisone drug  vincristine sulf,phase 2
902,ascorbic acid combination chemotherapy treating patients relapsed refractory lymphoma,dietary supplement  ascorbic acid drug  carboplatin drug  cisplatin drug  cytarabine drug  dexamethasone drug  etoposide drug  gemcitabine hydrochloride drug  ifosfamide laboratory biomarker analysis drug  oxaliplatin placebo questionnaire administration biological  rituximab,phase 2
903,ibritumomab tiuxetan treatment non follicular cd20  indolent lymphoma,drug  zevalin drug  rituximab drug   111 ibritumomab tiuxetan,phase 2
904,rituxan plus favid  idiotype vaccine  low grade non hodgkin lymphoma,biological  id klh,phase 2
905,clinical trial mitoxantrone hcl liposome injection patients relapsed dlbcl pt nkcl,drug  mitoxantrone hcl liposome inject,phase 2
906,bortezomib rituximab treating patients relapsed refractory b cell non hodgkin lymphoma,drug  bortezomib drug  rituximab procedure  antibody therapy procedure  biological therapy procedure  enzyme inhibitor therapy procedure  monoclonal antibody therapi,phase 2
907,allogenic stem cell transplantation  sct  non myeloablative conditioning patients relapse non hodgkin lymphoma  nhl ,drug  ibritumomab tiuxetan  zevalin ,phase 2
908,study entospletinib  ento  newly diagnosed dlbcl patients aaipi  1 treated chemiotherapi,drug  entospletinib drug  rituximab drug  cyclophosphamide drug  doxorubicin drug  vincristine drug  prednison,phase 1 phase 2
909,idiotype vaccine low grade non hodgkin lymphoma,biological  favid  id klh  active immunotherapi,phase 2
910,chemotherapy monoclonal antibody therapy treating patients b cell non hodgkin lymphoma relapsed following peripheral stem cell transpl,biological  rituximab drug  vinorelbine ditartr,phase 2
911,influenza vaccination patients receiving antineoplastic therapy non hodgkin lymphoma,biological  trivalent baculovirus expressed influenza ha vaccin,phase 2
912,chemoimmunotherapy early central nervous system  cns  prophylaxi,drug  liposomal cytarabin,phase 2
913,high dose intravenous methotrexate versus intrathecal methotrexate central nervous system prophylaxis dlbcl,drug  intrathecal methotrexate drug  high dose intravenous methotrex,phase 3
914,combination chemotherapy plus interferon alfa rituximab treating patients stage iii stage iv lymphoma,biological  recombinant interferon alfa biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 2
915,study incb050465 subjects relapsed refractory marginal zone lymphoma  citadel 204 ,drug  incb050465,phase 2
916,peripheral stem cell transplantation plus combination chemotherapy monoclonal antibody therapy treating patients non hodgkin lymphoma,biological  filgrastim biological  rituximab biological  sargramostim drug  carmustine drug  cisplatin drug  cyclophosphamide drug  dexamethasone drug  etoposide drug  gemcitabine hydrochloride drug  melphalan drug  paclitaxel procedure  bone marrow ablation stem cell support procedure  peripheral blood stem cell transplant,phase 2
917,combination chemotherapy  rituximab  ixazomib citrate treating patients non hodgkin lymphoma,drug  cyclophosphamide drug  cytarabine drug  doxorubicin hydrochloride drug  etoposide drug  ixazomib citrate laboratory biomarker analysis drug  methotrexate drug  prednisone biological  rituximab drug  therapeutic hydrocortisone drug  vincristine sulf,phase 1 phase 2
918,s0349 rituximab  cyclophosphamide  doxorubicin  vincristine  prednisone without oblimersen treating patients advanced diffuse large b cell non hodgkin lymphoma,biological  oblimersen sodium biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone laboratory biomarker analysi,phase 2
919,genetically engineered lymphocyte therapy peripheral blood stem cell transplant treating patients high risk  intermediate grade  b cell non hodgkin lymphoma,procedure  peripheral blood stem cell transplantation  pbsct  biological  filgrastim genetic  polymerase chain reaction biological  rituximab biological  genetically engineered lymphocyte therapy laboratory biomarker analysis drug  plerixafor procedure  autologous hematopoietic stem cell transplant,phase 1 phase 2
920,rituximab carmustine  cytarabine  etoposide  melphalan followed autologous hematopoietic stem cell transplantation treating patients b cell non hodgkin lymphoma,biological  rituximab drug  carmustine drug  cytarabine drug  etoposide drug  melphalan procedure  autologous bone marrow transplantation procedure  peripheral blood stem cell transplant,phase 2
921,dose finding study bromodomain  brd  inhibitor otx015 mk 8628 hematologic malignancies  mk 8628 001 ,drug  otx015 mk 8628,phase 1
922,entospletinib combination idelalisib adults relapsed refractory hematologic malign,drug  entospletinib drug  idelalisib,phase 2
923,rituximab treating young patients receiving chemotherapy b cell non hodgkin lymphoma b cell acute lymphoblastic leukemia,biological  rituximab,phase 2
924,swog 9704 chemoradiotherapy peripheral stem cell transplantation compared combination chemotherapy treating patients non hodgkin lymphoma,biological  rituximab drug  chop regimen drug  carmustine drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide drug  prednisone drug  vincristine sulfate procedure  bone marrow ablation stem cell support procedure  peripheral blood stem cell transplantation radiation  radiation therapi,phase 3
925,treatment good prognosis  bcl 6 negative diffuse large cell lymphoma chop r patients   61 years old ,drug  rituximab,nan
926,pf 06821497 treatment relapsed refractory sclc  castration resistant prostate cancer  follicular lymphoma,drug  pf 06821497,phase 1
927,pilot study pembrolizumab treatment disease relapse allogeneic stem cell transpl,drug  pembrolizumab,early phase 1
928,pembrolizumab untreated b cell non hodgkin lymphoproliferative disea,laboratory biomarker analysis biological  pembrolizumab,phase 2
929,antibiotic therapy antacids patients malt lymphoma stomach,drug  amoxicillin drug  bismuth subsalicylate drug  clarithromycin drug  metronidazole hydrochloride drug  omeprazole drug  tetracycline hydrochlorid,phase 2
930,phase 1 multiple ascending dose study ds 3201b japanese subjects lymphoma,drug  ds 3201b,phase 1
931,identification hematological malignancies therapy predication using micrornas diagnostic tool,nan,nan
932,administration anti cd19 chimeric antigen receptor transduced cells original transplant donor patients recurrent persistent b cell malignancies allogeneic stem cell transpl,procedure  allogeneic stem cell transplant biological  anti cd19 chimeric antigen receptor  transduced cel,phase 1
933,therapy non hodgkin lymphoma combination lenalidomide   rituximab  dexa  high dose ara c cisp,drug  rituximab drug  cisplatin drug  carboplatin drug  dexamethasone drug  cytarabine drug  lenalidomide drug  pegfilgrastim procedure  peripheral stem cell collect,phase 1 phase 2
934,prognostic value interim pet ct 2 cycles chemotherapy predicting progression non hodgkins lymphoma,nan,nan
935,monoclonal antibody therapy treating patients non hodgkin lymphoma relapsed high dose chemotherapy autologous stem cell transpl,biological  rituximab radiation  yttrium 90 ibritumomab tiuxetan,phase 1 phase 2
936,bryostatin 1 plus vincristine treating patients recurrent refractory hiv related lymphoma,drug  bryostatin 1 drug  vincristine sulf,phase 1
937,oblimersen  rituximab combination chemotherapy treating patients relapsed refractory aggressive non hodgkin lymphoma,biological  oblimersen sodium biological  rituximab drug  ifosfamide drug  carboplatin drug  etoposide biological  filgrastim biological  pegfilgrastim laboratory biomarker analysi,phase 1 phase 2
938,zevalin beam aggressive lymphoma,drug  ibritumomab tiuxetan procedure  beam chemotherapy autologous stem cell transplant,phase 3
939,combination chemotherapy plus rituximab treating patients relapsed non hodgkin lymphoma,biological  rituximab drug  cisplatin drug  cytarabine drug  dexamethasone drug  sargramostim,phase 2
940,activated cells expressing 2nd 3rd generation cd19 specific car  advanced b cell nhl  cll  sagan ,biological  cd19 car cells drug  fludarabine drug  cyclophosphamid,phase 1
941,combination study urelumab rituximab patients b cell non hodgkins lymphoma,biological  urelumab biological  rituximab,phase 1
942,radioimmunotherapy patients relapsed refractory non hodgkin lymphoma,biological  90 ibritumomab tiuxetan biological  rituximab radiation  indium 111 ibritumomab tiuxetan,phase 2
943,radiolabeled monoclonal antibody therapy high dose chemotherapy followed autologous peripheral stem cell transplant treating patients relapsed refractory non hodgkin lymphoma,biological  filgrastim biological  rituximab drug  carmustine drug  cytarabine drug  etoposide drug  melphalan procedure  peripheral blood stem cell transplantation radiation  yttrium 90 ibritumomab tiuxetan,phase 1
944,evaluation safety efficacy nipent  cytoxan  rituxan,drug  cytoxan drug  nipent drug  rituxan,phase 2
945,biological therapy plus monoclonal antibody therapy treating patients relapsed refractory non hodgkin lymphoma,biological  rituximab drug  agatolimod sodium,phase 1
946,mogamulizumab pembrolizumab treating patients relapsed refractory lymphoma,laboratory biomarker analysis biological  mogamulizumab biological  pembrolizumab,phase 1 phase 2
947,phase study bendamustine hydrochloride patients indolent b cell non hodgkin lymphoma,drug  bendamustine hydrochlorid,phase 1
948,combination chemotherapy rituximab treating patients hiv associated stage stage ii  stage iii  stage iv non hodgkin lymphoma,biological  rituximab drug  etoposide drug  doxorubicin hydrochloride drug  vincristine sulfate drug  prednisone drug  cyclophosphamide laboratory biomarker analysi,phase 2
949,pegfilgrastim combination chemotherapy without rituximab treating older patients aggressive b cell non hodgkin lymphoma,biological  pegfilgrastim biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulf,phase 2
950,peripheral stem cell transplantation treating patients relapsed low  intermediate grade non hodgkin lymphoma,biological  filgrastim drug  chemotherapy procedure  vitro treated peripheral blood stem cell transplantation procedure  peripheral blood stem cell transplantation radiation  radiation therapi,phase 2
951,rituximab combination chemotherapy treating patients stage ii  stage iii  stage iv diffuse large b cell non hodgkin lymphoma,biological  filgrastim biological  rituximab drug  carboplatin drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide drug  ifosfamide drug  prednisone drug  vincristin,phase 2
952,pentostatin rituximab treating patients low grade non hodgkin lymphoma chronic lymphocytic leukemia,biological  rituximab drug  pentostatin,phase 2
953,monoclonal antibody therapy treating patients relapsed refractory non hodgkin lymphoma,biological  apolizumab,phase 2
954,lymphocyte reconstitution administration pegfilgrastim versus filgrastim peripheral stem cell transpl,drug  pegfilgrastim drug  filgrastim,applicable
955,double blind  randomized controlled study cd20 positive diffuse b cell non hodgkin lymphoma subject,biological  tl011 biological  rituximab,phase 1
956,denileukin diftitox treating patients non hodgkin lymphoma,biological  denileukin diftitox,phase 2
957,long term extension study pci 32765  ibrutinib ,drug  pci 32765  ibrutinib ,phase 3
958,study assess efficacy safety ublituximab   tgr 1202 without bendamustine tgr 1202 alone patients previously treated non hodgkins lymphoma,drug  tgr 1202   ublituximab drug  tgr 1202 drug  tgr 1202   ublituximab   bendamustin,phase 2 phase 3
959,pegfilgrastim rituximab treating patients untreated  relapsed  refractory follicular lymphoma  small lymphocytic lymphoma  marginal zone lymphoma,biological  pegfilgrastim biological  rituximab flow cytometry procedure  biopsy immunohistochemistry staining method genetic  western blot,phase 2
960,safety  tolerability pharmacokinetics mrg 106 patients mycosis fungoides  mf   cll  dlbcl atl,drug  mrg 106,phase 1
961,cd19 cd22 chimeric antigen receptor  car  cells children young adults recurrent refractory cd19 cd22 expressing b cell malign,biological  cd19 cd22 car cells drug  fludarabine drug  cyclophosphamid,phase 1
962,pomalidomide dexamethasone treating patients relapsed refractory primary central nervous system lymphoma newly diagnosed relapsed refractory intraocular lymphoma,drug  dexamethasone laboratory biomarker analysis pharmacological study drug  pomalidomid,phase 1
963,phase 1 2 multi center study evaluating axicabtagene ciloleucel subjects refractory aggressive non hodgkin lymphoma  zuma 1 ,biological  axicabtagene ciloleucel,phase 1 phase 2
964,japanese phase ib ii copanlisib relapsed  indolent b cell nhl,drug  copanlisib  bay80 6946 ,phase 1 phase 2
965,safety efficacy revlimid®  lenalidomide  mabthera®  rituximab  non hodgkin lymphoma,drug  lenalidomide rituximab,phase 2
966,study velcade temsirolimus relapsed refractory non hodgkin lymphoma,drug  velcade drug  temsirolimu,phase 2
967,safety efficacy study immunotherapy rituximab interleukin 2 patients non hodgkin lymphoma,biological  rituximab biological  interleukin 2,phase 2
968,rituximab plus campath patients relapsed refractory low grade follicular  cd20 positive  b cell nhl,drug  campath  alemtuzumab ,phase 1 phase 2
969,phase ii carfilzomib plus lenalidomide rituximab treatment relapsed refractory mantle cell lymphoma,drug  carfilzomib drug  lenalidomide drug  rituximab,phase 1 phase 2
970,cells ebv specific ctls  advanced b cell nhl cl,biological  autologous syngeneic pbtls ebv ctl,phase 1
971,umbilical cord blood transplantation using myeloablative preparative regimen hematological disea,drug  fludarabine drug  cyclophosphamide radiation  total body irradiation drug  cyclosporine drug  mycophenylate mofetil biological  umbilical cord blood,applicable
972,molecular risk assessment planning treatment patients non hodgkin lymphoma,biological  rituximab drug  cyclophosphamide drug  doxorubicin hydrochloride drug  prednisone drug  vincristine sulfate genetic  microarray analysi,phase 2
973,study assess abp798 safe   effective treating non hodgkin lymphoma compared rituximab,drug  abp 798 drug  rituximab,phase 3
974,iodine 131 anti b1 antibody consolidation patients non hodgkin lymphoma following first line chop,drug  tositumomab iodine 131 tositumomab,phase 2
975,study safety efficacy c car011 b nhl pati,biological  c car011,phase 1
976,evaluation human immune responses influenza virus vaccination patients lymphoma,biological  inactivated influenza vaccin,phase 1
977,phase dose escalation study safety pharmacokinetics lam 002a patients non hodgkin lymphoma  lam 002a nhl ,drug  lam 002a drug  rituximab drug  atezolizumab,phase 1
978,bl22 immunotoxin treating patients non hodgkin lymphoma chronic lymphocytic leukemia,drug  bl22 immunotoxin procedure  antibody therapy procedure  biological response modifier therapy procedure  immunotoxin therapi,phase 1
979,pentostatin  cyclophosphamide  rituximab  mitoxantrone treating patients chronic lymphocytic leukemia low grade b cell canc,biological  filgrastim biological  pegfilgrastim biological  rituximab biological  sargramostim drug  cyclophosphamide drug  mitoxantrone hydrochloride drug  pentostatin genetic  fluorescence situ hybridization genetic  gene rearrangement analysis genetic  polymerase chain reaction genetic  protein expression analysis flow cytometry procedure  biopsi,phase 1 phase 2
980,safety pharmacokinetic study btct4465a  mosunetuzumab  single agent combined atezolizumab non hodgkin lymphoma  nhl  chronic lymphocytic leukemia  cll ,drug  btct4465a  mosunetuzumab  iv drug  atezolizumab drug  btct4465a  mosunetuzumab  sc,phase 1
981,combination chemotherapy treating children non hodgkin lymphoma,drug  asparaginase drug  cyclophosphamide drug  cytarabine drug  daunorubicin hydrochloride drug  dexamethasone drug  etoposide drug  mercaptopurine drug  methotrexate drug  methylprednisolone drug  mitoxantrone hydrochloride drug  prednisone drug  vincristine sulfate radiation  radiation therapi,phase 3
982,alisertib romidepsin treating patients relapsed refractory b cell cell lymphoma,drug  alisertib laboratory biomarker analysis drug  romidepsin,phase 1
983,study pralatrexate   gemcitabine b12   folic acid treat relapsed refractory lymphoproliferative malign,drug  pralatrexate injection drug  gemcitabine hydrochloride dietary supplement  vitamin b12 dietary supplement  folic acid,phase 1 phase 2
984,denileukin diftitox treating patients relapsed refractory non hodgkin lymphoma,biological  denileukin diftitox,phase 2
985,compassionate use trial ublituximab tgr 1202 combination single agents subjects currently receiving treatment ublituximab tgr 1202 tri,drug  tgr 1202 drug  tgr 1202   ublituximab,phase 2
986,trial oxaliplatin  cytosine arabinoside  dexamethasone rituxan  road  patients relapsed non hodgkins lymphoma,drug  oxaliplatin  cytosine arabinoside  dexamethasone rituxan  road ,phase 2
987,phase ii study evaluating combination pegylated liposomal doxorubicin dexamethasone treatment immunocompetent patients cerebral lymphoma relapsed refractory first line chemotherapy high dose methotrexate  mtxhd  high dose cytarabine ,drug  infusion myocet,phase 2
988,pembrolizumab ibrutinib treating patients relapsed refractory non hodgkin lymphoma,drug  ibrutinib laboratory biomarker analysis biological  pembrolizumab,phase 1
989,rituximab followed combination chemotherapy treating patients refractory recurrent non hodgkin lymphoma,biological  rituximab biological  sargramostim drug  epoch regimen drug  cyclophosphamide drug  doxorubicin hydrochloride drug  etoposide drug  prednisone drug  vincristine sulf,phase 2
990,low dose radiation therapy treating patients stage iv stomach malt lymphoma,radiation  radiation therapi,applicable
991,copanlisib rituximab marginal zone lymphoma pati,drug  copanlisib,phase 2
992,study alisertib  mln8237  adults aggressive non hodgkin lymphoma,drug  alisertib,phase 2
993,safety pharmacokinetics  pk  study venetoclax participants non hodgkin lymphoma,drug  venetoclax drug  cyclophosphamide drug  obinutuzumab drug  rituximab drug  doxorubicin drug  vincristine drug  prednison,phase 1 phase 2
994,lenalidomide blinatumomab treating patients relapsed non hodgkin lymphoma,biological  blinatumomab laboratory biomarker analysis drug  lenalidomid,phase 1
995,obinutuzumab marginal zone lymphoma,drug  obinutuzumab,phase 2
996,cyclophosphamide w w rituximab peripheral stem cell transplantation patients recurrent non hodgkin lymphoma,biological  filgrastim biological  rituximab drug  carmustine drug  cisplatin drug  cyclophosphamide drug  etoposide procedure  bone marrow ablation stem cell support procedure  peripheral blood stem cell transplantation radiation  radiation therapi,phase 2
997,study ym155 plus rituximab subjects non hodgkin lymphoma received prior treat,drug  ym155 biological  rituximab,phase 2
998,carfilzomib plus belinostat relapsed refractory nhl,drug  carfilzomib drug  belinostat,phase 1
999,monoclonal antibody therapy  combination chemotherapy  peripheral stem cell transplant treating patients relapsed refractory non hodgkin lymphoma,drug  carmustine drug  cytarabine drug  etoposide drug  melphalan procedure  peripheral blood stem cell transplantation radiation  tositumomab iodine 131 tositumomab,phase 2
